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Amyotrophic Lateral Sclerosis (ALS) is a rapidly fatal neurological disease characterized by the 
degeneration of motor neurons involved in voluntary muscle control.  Clinical disease 
management is hindered by both a lengthy diagnostic process and the absence of effective 
long-term treatments.  The identification and characterization of novel protein biomarkers could 
improve the speed and accuracy of disease diagnosis, and assist in predicting and tracking 
disease progression.  Additionally, the utilization of such biomarkers could also expedite the 
development of effective treatments by both providing insight into disease pathogenesis, and 
improving the efficacy of clinical trials.  In this work, I examined two cerebrospinal fluid (CSF) 
proteins, cystatin C and free hemoglobin, for biomarker utility and functional relationships with 
disease pathogenesis.  Cystatin C is a constitutively expressed cysteine protease inhibitor that 
appears to be reduced in the CSF of ALS patients.  I evaluated cystatin C concentration by 
ELISA in CSF and plasma samples from ALS patients, normal controls, and neurological 
disease controls.  These data were used to evaluate cystatin C as a diagnostic, surrogate, and 
prognostic biomarker in ALS.  Plasma cystatin C was equally elevated in ALS patients and 
disease controls, demonstrating no biomarker utility.  However, CSF levels were confirmed to 
be lower in ALS patients than in healthy controls, and may possess diagnostic utility when used 
in conjunction with other biomarkers.  CSF cystatin C also exhibited potential for one surrogate 
biomarker application, and for prognostic biomarker utility.  The trends in CSF cystatin C 
abundance suggest a neuroprotective role for cystatin C in ALS.  Accordingly, reductions in CSF 
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cystatin C may contribute to disease development through the loss of a protective function 
mediated by cysteine protease inhibition.  CSF free hemoglobin levels were also measured by 
ELISA, and were evaluated for utility as a biomarker of blood-CNS barrier damage in ALS.  The 
proportion of ALS patients exhibiting elevated CSF free hemoglobin was higher than in either 
control group, suggesting that blood-CNS barrier damage may occur in this disease.  Overall, 
the results of this work identify and clarify potential biomarker applications of two CSF proteins, 
and also provide new insight into potential pathogenic mechanisms of ALS. 
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1.0  INTRODUCTION 
1.1 CONTROL OF VOLUNTARY MOVEMENT 
1.1.1 Voluntary Movement and Human Functioning 
In humans, voluntary movement can be described as intentional, goal-directed movement that is 
initiated by conscious choice.  It is how we actively interact with our world, and includes the 
actions required for speech, facial expression, locomotion, and nearly all of the physical 
activities we carry out in our daily lives.  In contrast, involuntary movements are those that we 
cannot actively control, such as heartbeat and the smooth muscle contractions of the 
gastrointestinal tract that aid in digestion.  Additionally, some voluntary movements, such as 
breathing and blinking, can be controlled by both involuntary and voluntary mechanisms.  Many 
voluntary movements are required for survival, and others are important in maintaining overall 
health and well-being. 
1.1.2 Production of Voluntary Movement 
Like all human behaviors, voluntary movements are controlled by the central nervous system 
(CNS).  The production of voluntary movement is a complex process that includes movement 
conception, planning, and execution.  Once we decide to initiate a movement, multiple brain 
regions contribute to movement planning, which determines the timing, speed, direction, and 
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coordination of the movement.  This large amount of information is condensed into a specific 
motor plan, which is transmitted to the motor cortex primarily from the supplementary motor, 
premotor, and posterior parietal areas.  Execution of the planned movement occurs via a two-
neuron pathway that begins in the motor cortex (Figure 1).  Upper motor neurons (UMNs)  
located in the motor cortex receive planned movement instructions and transmit this information 
via long axons that descend into the brain stem and the spinal cord.  There, they synapse 
primarily on lower motor neurons (LMNs) in cranial nerve nuclei and the ventral horn of the 
spinal cord.  The axons of these LMNs exit the CNS and form cranial nerves or peripheral 
nerves before forming synapses with target muscle fibers.  The synchronized stimulation of 
muscle fibers generates the muscle contractions that produce voluntary movement. 
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Figure 1.  Schematic of upper and lower motor neurons and their targets.  The cell bodies of 
UMNs (upper left) are located in the motor cortex.  Their axons descend into the brain stem and 
spinal cord, where they form synapses on LMNs in cranial nerve nuclei and the spinal ventral 
horn (lower left).  Lower motor neurons (at right) send their axons into the periphery, where they 
innervate muscles of the face and body.  Adapted from [1]. 
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1.2 MOTOR NEURON DISEASES 
Clinical disorders that result primarily from the selective degeneration of upper and/or lower 
motor neurons are referred to as motor neuron diseases.  These disorders arise from a wide 
variety of genetic and environmental causes, and result in varying degrees of muscle spasticity, 
weakness, and paralysis.  The reasons that motor neurons are preferentially affected by these 
disorders are not fully understood, but it appears that motor neurons may demonstrate 
increased vulnerability to toxic and metabolic stressors due to their large size, high metabolic 
activity, sensitivity to mitochondrial dysfunction, and reduced ability to buffer calcium [2].  Motor 
neuron diseases are primarily stratified by their etiology, typical age at symptom onset, and the 
neuronal populations that they affect (Table 1).   
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Table 1.  Motor neuron diseases.  AD = autosomal dominant; ALS = amyotrophic lateral 
sclerosis; ALS2 = amyotrophic lateral sclerosis 2 (juvenile) gene; AR = autosomal recessive; AR 
= androgen receptor gene; dHMN = distal hereditary motor neuropathy; PMA = progressive 
muscular atrophy; HSP = hereditary spastic paraplegia; JPLS = juvenile primary lateral 
sclerosis; LMN = lower motor neuron; PLS = primary lateral sclerosis; SBMA = spinal bulbar 
muscular atrophy; SMA = spinal muscular atrophy; SMN1 = survival of motor neuron 1 gene; 
UMN = upper motor neuron; XD = X-linked dominant; XR = X-linked recessive.  Modified from 
[1, 3-8]. 
Disease 
Age of 
Onset 
Affected 
Motor 
Neurons 
Clinical Features 
Associated 
Genes 
Inheritance 
of Familial 
Forms 
ALS 
Adulthood; 
rare 
juvenile 
forms 
UMNs 
and 
LMNs 
Rapidly progressive 
muscle weakness, atrophy, 
and spasticity; rare 
cognitive dysfunction 
Many 
Most AD; 
some AR, 
XD 
HSP 
Early 
childhood 
to 
adulthood 
UMNs 
Slowly progressive 
spasticity and weakness in 
the lower limbs 
Many 
Most AD; 
some AR, 
XR 
PLS Adulthood UMNs 
Progressive spasticity and 
muscle weakness 
Unknown Idiopathic 
JPLS Childhood UMNs 
Progressive spasticity and 
muscle weakness 
ALS2 AR 
SMA 
Infantile to 
adulthood 
LMNs 
Muscle weakness and 
atrophy; time course varies 
from slowly progressive to 
rapidly fatal 
SMN1 AR 
SBMA Adulthood LMNs 
Slowly progressive limb 
and bulbar muscle 
weakness, fasciculations, 
and atrophy 
AR XR 
dHMN 
Childhood 
to 
adulthood 
LMNs 
Slowly progressive 
weakness in distal muscles 
Many 
Most AD; 
some AR, 
XD 
PMA Adulthood LMNs 
Muscle weakness and 
atrophy; time course varies 
from slowly progressive to 
rapidly fatal 
A few 
possible 
genes 
Almost all 
idiopathic 
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1.3 AMYOTROPHIC LATERAL SCLEROSIS 
Amyotrophic lateral sclerosis (ALS) is the most common form of motor neuron disease 
worldwide.  It is characterized by the rapid degeneration of both the upper and lower motor 
neurons involved in voluntary muscle control, leading to progressive paralysis, respiratory 
compromise, and death.   
1.3.1 Epidemiology  
The incidence of ALS is relatively constant at 1-3/100,000 worldwide, with the exception of a 
few high-risk areas around the Pacific rim [9].  The prevalence of ALS is approximately 4-
6/100,000 [10], and the lifetime risk is 1-2/1,000 [11].  The incidence of ALS is higher in men 
than in women by a ratio of ~1.5:1.  Clinical onset usually occurs between ages 45 and 60 [10], 
but rare juvenile forms become symptomatic during childhood [12].  The majority of ALS cases 
arise sporadically, but in around 10% of patients, a familial link is observed [13].  Environmental 
and occupational risk factors for ALS include ingestion of cycad seeds, smoking, head injuries, 
and exposure to pesticides, insecticides, heavy metals, and electromagnetic fields [9].   
1.3.2 Clinical Characteristics  
Clinically, ALS is characterized by the rapidly progressive development of muscle spasticity and 
paralysis, usually leading to death within 3-5 years of symptom onset.  The most frequent 
causes of death are respiratory complications resulting from paralysis of the muscles required 
for normal breathing.  However, ~10% of patients survive more than 10 years after symptom 
onset. 
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ALS can affect nearly all voluntary muscles, but the sphincters involved in bowel and 
bladder continence are unaffected.  Voluntary muscles of the eyes are also relatively spared, 
but deficits in eye movements are observed in some patients [14].  Clinical symptoms usually 
begin in a single muscle group and are characterized by signs of UMN damage (spasticity, 
hyperreflexia, and weakness) and signs of LMN damage (weakness, atrophy, fasciculations, 
hyporeflexia, and hypotonia) [15].  Disease onset usually begins in the muscles of the limbs 
(~75% of cases) or the bulbar muscles (~20% of cases) [16], which control speech and 
swallowing, but the disease can also present with symptoms in the muscles of the trunk or with 
cognitive losses.  Following clinical onset, symptoms steadily worsen at the point of onset, and 
spread to adjacent and distant muscle groups until most voluntary muscles are affected.  Both 
the rate of disease progression and the ratio of UMN to LMN involvement are highly variable 
between patients [15].    
Although ALS was originally thought to exclusively affect motor neurons, it is now known 
that a significant proportion of patients (10-50%) exhibit mild frontotemporal cognitive and 
behavioral deficits [17].  In contrast to the motor symptoms of ALS, these cognitive deficits do 
not appear to progress over time or, at most, they progress very slowly [17].  A smaller 
percentage of patients (~15%) meet the diagnostic criteria for both ALS and an overt dementia 
with clinical and neuropathological characteristics similar to frontotemporal lobar degeneration 
(FTLD) [17].  In fact, due to extensive overlap between specific pathological findings in ALS and 
FTLD, it has been proposed that these disorders are actually syndromic variants of a single 
neurodegenerative disease [18]. 
1.3.3 Diagnosis 
ALS is diagnosed according to the Revised El Escorial criteria [19], which require the presence 
of both upper and lower motor neuron signs in at least three spinal regions, or in the bulbar 
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region and at least two spinal regions.  Additionally, there must be evidence of the progressive 
spread of ALS pathology to adjacent or distant CNS locations, and there must be no 
electrophysiological or neuroimaging evidence of other disease processes that could produce 
the observed signs [19].   
There are a number of diseases that can clinically mimic ALS at presentation, which 
must be ruled out during the diagnostic process.  These include other motor neuron diseases 
(Table 1), disorders of the peripheral nerves, and diseases that can affect the motor cortex or 
spinal cord such as neurofibromatosis type I and various neoplasms [20].  Additionally, because 
the diagnosis of ALS is based almost exclusively on clinical criteria, a substantial amount of 
disease progression is often required before the diagnosis can be confirmed.  For this reason, 
there is usually a lengthy delay (median ~14 months) between patient presentation following 
symptom onset and the final confirmation of an ALS diagnosis [21].  Even with this seemingly 
conservative diagnostic process, there is still a 10-15% false positive rate following definitive 
ALS diagnosis using the revised criteria [20].  Clearly, additional biomedical research is needed 
in order to develop a faster and more accurate diagnostic protocol.  
1.3.4 Neuropathology 
ALS is characterized by the loss of large-diameter UMNs, known as Betz cells, in layer V of the 
motor cortex, as well as large LMNs located in the brainstem nuclei and the ventral horn of the 
spinal cord [22].  This is accompanied by degeneration and astrocytic gliosis of the descending 
corticospinal tracts, which are formed by the descending axons of UMNs [22].  Additionally, 
there is degeneration of the neuromuscular junctions, where the axons of LMNs synapse with 
peripheral target muscles [10].  Affected muscle groups display denervation atrophy [22].   
Surviving motor neurons exhibit cytoplasmic shrinkage with lipofuscin granules, 
mitochondrial abnormalities, and occasional fragmentation of the Golgi apparatus [1, 22].  
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Additionally, degenerating neurons and glial cells often contain a number of characteristic 
protein aggregates, including Bunina bodies, ubiquitinated inclusions, hyaline inclusions, and 
axonal spheroids (Table 2) [1].  Notably, Bunina bodies contain cystatin C proteins, and are 
relatively specific for ALS [23].  
 
Table 2.  Intraneuronal inclusions in ALS.  FALS = familial ALS; SALS = sporadic ALS; TDP-43 
= transactivation response DNA-binding protein with molecular weight 43 kDa.  Adapted from [1, 
2, 23-25].  
Inclusion Location Features Contents Comments 
Bunina bodies 
Cytoplasm and 
dendrites of 
LMNs and 
UMNs (rarely); 
astrocytes 
Round; 
eosinophilic; 
hyaline 
Cystatin C; 
transferrin; 
occasionally 
peripherin 
Present in ~70% 
of SALS and 
some FALS; 
ubiquitin 
negative 
Ubiquitinated 
"Skein-like" 
inclusions 
Predominantly in 
the cytoplasm of 
LMNs; also 
found in UMNs 
Filamentous 
TDP-43 and 
other proteins 
Neurofilament 
and tau negative 
Ubiquitinated 
"Lewy body-
like" inclusions 
Predominantly in 
the cytoplasm of 
LMNs; also 
found in UMNs 
Round and 
dense 
TDP-43, 
peripherin, and 
other proteins; 
may contain 
neurofilament 
proteins 
Less common 
than "Skein-like" 
inclusions 
Hyaline 
inclusions 
Cytoplasm of 
LMNs 
Large and 
multifocal 
Neurofilament 
proteins, 
peripherin, 
others 
Weakly positive 
for ubiquitin 
Axonal 
spheroids 
Proximal axons 
of LMNs 
Hyaline 
Neurofilament 
proteins, 
peripherin, 
others 
Differentiated 
from hyaline 
inclusions by 
location only 
 
 
 
Regarding the longitudinal development of ALS neuropathology, motor neuron 
degeneration typically begins focally, in the UMNs and LMNs that innervate a single peripheral 
body region [15].  Following clinical onset, motor neuron pathology and cell death spread 
contiguously to adjacent regions of the motor cortex and spinal cord [15].  Due to the differing 
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somatotopic anatomy of these two CNS structures, new UMN and LMN signs typically spread to 
different peripheral body regions, or to the same regions at differing times [15].  However, by 
end-stage disease, UMN and LMN signs are often widespread and symmetric due to spatial and 
temporal summation among and between CNS regions [15].  Notably, the initial site of disease 
pathology, the ratio of UMN to LMN degeneration, and the rate of contiguous disease spread 
are each highly variable and independent from each other [15]. 
1.3.5 Genetics 
The vast majority of ALS cases arise in individuals with no family history of motor neuron 
disease, and are referred to as sporadic ALS (SALS).  However, in approximately 10% of cases, 
a heritable genetic link is observed.  These familial ALS (FALS) cases result from mutations in 
numerous proteins with a wide variety of biological functions (Table 3).  Mutations of the protein 
copper-zinc superoxide dismutase (SOD1) are the most prevalent cause of FALS, and account 
for ~20% of FALS (~2% of all ALS cases).  Interestingly, over 100 distinct mutations of this 
protein have been identified in FALS patients [26].  Most of these mutations result in a single 
amino acid substitution, and substitutions in more than one third of the 153 amino acids that 
compose the protein have been observed [26].  Other mutations result in amino acid deletions 
or protein truncation [26].  
SOD1 is a ubiquitously expressed, cytosolic enzyme that catalyzes the conversion of 
superoxide into molecular oxygen and hydrogen peroxide.  Because this process serves to 
protect against the generation of damaging reactive oxygen species, it was originally assumed 
that SOD1 mutations caused ALS through the loss of this protective function, and subsequent 
oxidative damage to motor neurons.  However, this is unlikely, as SOD1 knockout mice do not 
develop motor neuron disease [27], and many ALS-causing SOD1 mutations do not eliminate 
dismutase activity [28-30].  It is now thought that SOD1 mutations result in a toxic gain of 
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function, which likely results from the propensity of the mutant protein to aggregate and disrupt 
intracellular processes, as well as the abnormal translocation of the mutant protein into the 
mitochondrial compartment, with subsequent mitochondrial dysfunction [31].   
The discovery of SOD1 mutations in ALS led to the development of multiple animal 
models using rodents, dogs, zebrafish, and C. elegans [31].  To date, the vast majority of ALS 
research has been completed using rodents that overexpress mutant human SOD1.  These 
animals exhibit motor neuron degeneration and associated muscle weakness and atrophy, as 
well as reduced lifespan [31, 32].  Studies of these rodents have confirmed that mutant SOD1 
acts via a toxic gain of function in this disease model, as these animals retain their endogenous 
SOD1 activity but still develop motor neuron disease, and also because the expression level of 
the mutant SOD1 protein is directly proportional to the severity of the resulting disease 
phenotype [33].  Research using transgenic ALS models has led to large advances in our 
understanding of ALS pathophysiology.  However, it is important to note that SOD1-based 
rodent models do not fully replicate the pathological processes present in human FALS, and 
especially SALS. 
A recent focus within the field of ALS research has centered on the discovery of 
mutations in an RNA processing protein called transactivation response DNA-binding protein 
with molecular weight 43 kDa (TDP-43).  Mutations in the gene that encodes this protein, 
TARDBP, account for <5% of familial ALS (<1% of all ALS), but the wild type protein is a major 
component of neuronal inclusion bodies found in patients with SALS and FTLD.  The discovery 
of mutated TDP-43 in ALS, in addition to several other mutated proteins (Table 3), is currently 
leading to the development of multiple novel animal models of FALS [31]. 
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Table 3.  Genes that can cause FALS or SALS.  AD = autosomal dominant; AR = autosomal 
recessive; XD = X-linked dominant.  Modified from [3, 9]. 
Designation 
Gene or 
Locus 
Protein Inheritance Onset 
ALS1 SOD1 Superoxide dismutase 1 AD Adult 
ALS2 ALS2 Alsin AR Juvenile 
ALS3 18q21 Unknown AD Adult 
ALS4 SETX Senataxin AD Juvenile 
ALS5 15q15 Unknown AR Juvenile 
ALS6 FUS/TLS RNA-binding protein FUS AD, AR Adult 
ALS7 20p13 Unknown AD Adult 
ALS8 VAPB Vesicle-associated membrane protein B AD Adult 
ALS9 ANG Angiogenin AD Adult 
ALS10 TARDBP TDP-43 AD Adult 
ALS11 FIG4 Polyphosphoinositide phosphatase AD Adult 
ALSX Xp11-q12 Unknown XD Adult 
ALS DCTN1 Dynactin AD Adult 
ALS NF-H Neurofilament heavy chain AD, sporadic Adult 
SALS DPP6 Dipeptidyl aminopeptidase-like protein 6 Sporadic N/A 
SALS ELP3 Elongator protein 3 Sporadic N/A 
SALS KIFAP3 Kinesin-associated protein 3 Sporadic N/A 
SALS UNC13A Protein unc-13 homolog A Sporadic N/A 
ALS-FTLD1 9q21-q22 Unknown AD, sporadic Adult 
ALS-FTLD2 
9p21.3-
p13.2 
Unknown AD Adult 
ALS-FTLD3 CHMP2B Chromatin-modifying protein Sporadic Adult 
ALS-FTLDP MAPT Microtubule-associated protein tau AD Adult 
 
 
 
The genetics of SALS are less clear, but mutations in FALS-causing genes are 
occasionally identified in this population [34-36].  The presence of these mutations is thought to 
result from de novo mutation, misattributed paternity, and incomplete penetrance.  Additionally, 
genome-wide association studies have identified several putative susceptibility genes including 
ANG, APE1, DPP6, FLJ10986, HFE, hOGG1, IL18RAP, ITPR2, LOXHD1, MAGI2, PTPRT, 
SMN1, and VEGF [9, 37].  Further validation studies are required to determine the impact of 
these genes on SALS development.   
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1.3.6 Etiology  
ALS is a complex, multifactorial disease with a variable phenotype and a wide variety of 
functionally divergent genetic and environmental correlates.  It may be more accurate to refer to 
this disorder as a syndrome, with multiple distinct pathophysiological mechanisms leading to a 
similar clinical outcome.  However, there still appears to be a number of characteristic 
pathological processes that are common to both the familial and sporadic forms of the disease, 
including excitotoxicity, oxidative stress, mitochondrial dysfunction, protein aggregation, 
cytoskeletal dysfunction, and RNA processing defects [2, 3, 10].  These processes most likely 
present in varying degrees in different ALS populations, but may lead to a similar final pathway 
of selective motor neuron degeneration, most likely via an apoptotic mechanism [2]. 
1.3.6.1 Excitotoxicity 
Rapid firing of glutamatergic inputs exposes both UMNs and LMNs to large amounts of 
glutamate.  If left unchecked, excessive stimulation of calcium-permeable AMPA glutamate 
receptors can allow toxic levels of calcium to enter the cells, leading to glutamate-mediated 
excitotoxicity.  Motor neurons are inherently sensitive to excitotoxicity relative to other neuronal 
types due to a lower proportion of the GluR2 subunit in their glutamate receptors [38].  
Under physiologic conditions, astrocytes rapidly remove excess glutamate directly from 
the synapse via uptake by the glial glutamate transporter EAAT2.  However, EAAT2 levels are 
reduced in the motor cortex and spinal cord of SALS patients [39-42], and in the spinal cords of 
transgenic rodents expressing mutant SOD1 [43, 44].  This finding indicates that both motor 
neuron populations may have increased exposure to excess glutamate in ALS, and suggests 
that excitotoxicity may be a common pathogenic mechanism in both SALS and FALS [10]. 
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1.3.6.2 Oxidative Stress 
Free radicals and other reactive oxygen species (ROS) are highly reactive and can damage 
proteins, lipids, and nucleic acids.  Oxidative stress occurs when there is an imbalance between 
ROS production and clearance, and subsequent cellular damage is not adequately repaired 
[45]. 
Markers of protein oxidation and oxidative damage are present in the post-mortem motor 
cortex and spinal cord in SALS patients, and in the spinal cord in FALS patients.  Cerebrospinal 
fluid (CSF) collected from symptomatic ALS patients also contains increased markers of 
oxidative stress [46-49].  The causal relationship between mutated SOD1 and FALS also seems 
to support the hypothesis that oxidative stress is an integral component of ALS pathogenesis.  
However, full dismutase activity is maintained in some ALS-causing SOD1 mutations [29, 50], 
and SOD1 knockout mice do not develop motor neuron disease [27], both indicating that SOD1 
mutations lead to ALS pathogenesis through a toxic gain of function, rather than the loss of free 
radical scavenging activity.  Nonetheless, there is extensive evidence that oxidative damage 
does occur in all forms of ALS, and this process has clear pathophysiologic relationships with 
other proposed mechanisms of ALS pathogenesis including excitotoxicity, mitochondrial 
dysfunction, protein aggregation, cytoskeletal dysfunction, glial involvement, and RNA 
processing dysfunction [45].   
The source of oxidative stress in ALS is unclear, but excess production of ROS may 
result from mitochondrial dysfunction or the inappropriate activation of ROS-generating 
pathways [31]. 
1.3.6.3 Mitochondrial Dysfunction 
Mitochondrial involvement in ALS pathogenesis is strongly suggested by histopathological 
findings in both SALS and FALS.  Post-mortem evaluation of motor neurons in the brain and 
spinal cord, and skeletal muscle cells, reveals dilated mitochondria with extensive vacuole 
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formation and disorganized cristae [51-53].  Impaired mitochondrial respiration and increased 
uncoupling protein levels have also been reported in spinal cord tissue and muscle biopsies 
from ALS patients [54-58].  Similar mitochondrial pathology is observed in rodent models of 
FALS, beginning long before motor neuron loss and symptom onset [59-61].  This suggests that 
mitochondrial dysfunction may be a primary component of disease pathogenesis, rather than a 
secondary result of the degenerative process [10]. 
In SOD1-mediated FALS, multiple forms of mutant SOD1 protein have been shown to 
localize to mitochondria and affect multiple components of the electron transport chain.  
Additionally mitochondrial accumulation of SOD1 appears to reduce the calcium buffering 
capacity of mitochondria [62], which could also contribute to excitotoxic pathways of neuronal 
death [10].  In contrast, wild type SOD1 does not often localize to mitochondria, and it remains 
unclear what causes mitochondrial pathology in SALS [10].  Oxidative injury may lead to 
mitochondrial damage in both ALS types, and the resulting dysfunction may contribute to motor 
neuron degeneration through the activation of cell death pathways and further increases in free 
radical production and oxidative stress [10, 31]. 
1.3.6.4 Protein Misfolding and Aggregation 
Several types of abnormal protein aggregates are pathological hallmarks of ALS, including 
ubiquitinated inclusions, Bunina bodies, and neurofilamentous hyaline inclusions, but their role 
in disease pathogenesis is unknown [2].  These protein aggregates may form as a protective 
cellular response, or they may contribute to disease development or progression through 
pathological signaling activity, the sequestration of essential proteins, and the disruption of 
normal cytoarchitecture. 
In SOD1-mediated FALS and animal models, mutant SOD1 proteins misfold selectively 
in motor neurons, and then form aggregates within the cytoplasm [63-65].  These aggregates 
may damage motor neurons through the sequestration of essential cellular proteins such as 
 16 
neuronal glutamate transporters, the copper chaperone for SOD1, and heat shock proteins 40 
and 70, which have all been found to co-immunoprecipitate with aggregated SOD1 [66, 67].  
Misfolded or aggregated mutant SOD1 may also damage motor neurons through (1) altered 
interactions with binding partners, such as the inappropriate activation of NADPH oxidase 2 
(NOX2) and resulting overproduction of superoxide anions, (2) deleterious effects of aberrant 
SOD1 secretion [68, 69], and (3) translocation to the mitochondria, potentially leading to 
reduced energy generation, increased free radical production, reduced calcium buffering 
capacity, and the initiation of apoptosis [31]. 
Mutant SOD1 expression and misfolding in astrocytes and microglia also appears to 
contribute to motor neuron degeneration in ALS.  In rodent models of ALS, selective deletion of 
mutant SOD1 in both glial cell types slowed disease progression, suggesting that glial cells may 
contribute to non-cell-autonomous pathways of motor neuron degeneration in ALS pathogenesis 
[70, 71]. 
1.3.6.5 Cytoskeletal Dysfunction and Defective Axonal Transport 
The axons of motor neurons are the longest in the human body, and contain ~99% of the 
cellular cytoplasm [31].  As a result, organized axonal structure and transport is particularly 
important in maintaining the health and proper functioning of motor neurons [2], and motor 
neurons with the largest caliber axons are selectively vulnerable in both human ALS [72] and 
transgenic rodent models [43, 61]. 
In the motor neurons of ALS patients, cytoskeletal intermediate-filament proteins 
including neurofilament proteins (the most abundant axonal structural protein), peripherin, and 
α-internexin commonly aggregate into hyaline inclusions in the cell body and proximal axons [2, 
10].  It is unclear whether these protein aggregates represent a protective response or a 
pathogenic mechanism, but it has been proposed that their presence may disrupt cytoskeletal 
architecture and impair axonal transport [10].  Similar axonal aggregates are observed in 
 17 
rodents expressing mutant SOD1, and these animals demonstrate both defective axonal 
transport and retraction from the neuromuscular junction long before motor neuron degeneration 
and symptom onset [2, 10, 31].  Additionally, the deletion of all axonal neurofilaments from 
these transgenic rodents has been shown to prolong survival [73, 74].  These findings support 
an early, pathogenic role for the aggregation of structural proteins in ALS motor neurons.   
The importance of axonal structural organization in motor neuron survival is further 
reinforced by rodent studies showing that the overexpression of human neurofilament protein, 
peripherin or α-internexin all result in motor neuron degeneration [75-79].  In human disease, a 
role for structural axonal disorganization in disease pathogenesis is suggested by the discovery 
of gene deletions for the neurofilament heavy chain in ~1% of SALS patients [80-82].  
Additionally, defects in axonal transport are suggested as a potential pathogenic mechanism by 
the discovery of mutations in several transport-related proteins in both FALS and SALS, 
including VAPB, DCTN1, and KIFAP3 (Table 3).   
1.3.6.6 RNA Processing Defects 
Recently, FALS-causing mutations have been identified in several genes involved in RNA 
processing, including SETX, ELP3, FUS/TLS, TARDBP, ALS2, and ANG (Table 3) [3].  These 
genes code for proteins that contribute to multiple stages of RNA metabolism, including 
transcription, splicing, stabilization, and translation [3].  Additionally, the wild type protein that is 
encoded by the TARDBP gene, TDP-43, was also found to be a major component of neuronal 
inclusion bodies in patients with SALS [83] and some forms of FALS [31].  Similar TDP-43 
positive inclusions are also characteristic of FTLD, leading to the hypothesis that these 
disorders are syndromic variants of a common pathogenic process [18].  These findings suggest 
a potential role for defective RNA processing in the pathogenesis of both forms of ALS, as well 
as FTLD.   
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However, the mechanisms by which these RNA processing proteins contribute to the 
development of motor neuron disease remain unclear.  Most of these proteins have alternative 
biological functions that are not related to RNA metabolism, but could be the source of 
pathogenic behavior by mutant proteins.  Additionally, mutant proteins may display an unrelated 
toxic gain of function, as implied by the autosomal dominant inheritance pattern displayed by 
several of the mutations [3].  
1.3.7 Treatment  
Currently, the clinical management of ALS primarily consists of supportive therapies, which 
alleviate the treatable symptoms of the disease rather than slowing or preventing disease 
progression [84].  This is because there are virtually no available treatments that effectively act 
on the underlying pathophysiology to alter the disease process.  In fact, there is only one drug, 
Riluzole, that is currently approved by the FDA to treat ALS, and this therapy increases life span 
by only two to three months [85].  Other treatments designed to modify individual disease 
mechanisms have shown promise in rodent disease models, but have been largely 
unsuccessful in human populations [86, 87].  This discrepancy may arise from differences 
between human disease and the animal models used in drug development, or from extreme 
disease heterogeneity and resulting weaknesses in clinical trial design [22, 84, 88]. 
Riluzole is the only drug that has been proven to be effective in clinical trials [89, 90].  It 
was developed to alleviate the effects of excitotoxicity, and is thought to work via 
antiglutamatergic effects on glutamic acid release, NMDA receptor signaling, and voltage-
dependent sodium channel function [91].  Unfortunately, other antiglutamatergic agents, 
including gabapentin, topiramate, verapamil, lamotrigine and dextromethorphan, have not been 
effective in clinical trials [2].  These findings suggest that Riluzole may exert its therapeutic 
effects via an alternate pharmacologic mechanism. 
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Due to the extensive evidence for oxidative stress as a component of ALS pathogenesis, 
numerous antioxidants have been tested for treatment utility in both transgenic rodent models 
and clinical populations.   Compounds examined include vitamin E, N-acetyl-L-cyteine, 
Selegiline, and D-Penicillamine.  Many of these antioxidants have shown efficacy in SOD1-
based rodent models, but clinical trials have all been negative or inconclusive [2, 84].  Similar 
findings have been reported for drugs targeting mitochondrial dysfunction which, if effective, 
would secondarily reduce the generation of oxidative stressors.  Creatine, in particular, showed 
strong efficacy in transgenic mice [92] but provided no clinical benefit in three human trials [2, 
93, 94].  However, KNS-760704, a newer mitochondrial neuroprotectant drug with an unknown 
mechanism of action, has shown promise in animal models and early phase clinical trials, and 
will be fully evaluated for efficacy in a phase 3 trial starting this year [95]. 
Another new drug that has progressed to clinical trials is ISIS-SOD1-Rx, is an antisense 
molecule that interferes with translation of the SOD1 mRNA transcript.  This drug was 
developed to reduce the production of toxic mutant SOD1 in FALS patients with SOD1 
mutations (~20% of FALS and ~2% of all ALS).  ISIS-SOD1-Rx reduced SOD1 expression and 
increased lifespan in a transgenic rats overexpressing mutant human SOD1, supporting its 
potential for therapeutic efficacy in select FALS patients [96].  It is now being tested for safety in 
phase 1 clinical trials.   
Clinical trials using neurotrophic factors, including ciliary neurotrophic growth factor and 
insulin-like growth factor, have been inconclusive [84], possibly due to low bioavailability and 
poor access to motor neurons [2].  Anti-inflammatory and anti-apoptotic agents have also been 
tested without success [2, 97].   
Several non-pharmacologic treatments have also been examined.  Most trials were 
inconclusive, but therapeutic exercise marginally slowed the rate of functional losses and 
enteral tube feeding slightly improved survival in limb and bulbar onset patients [98].   
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Some of the compounds and techniques which have yielded inconclusive results in 
clinical trials may possess some treatment efficacy that was not identified.  In many trials, small 
effects, or effects limited to specific patient sub-populations, may have been undetectable due 
to several common weaknesses in clinical trial design.  The heterogeneous nature of ALS 
disease etiology and phenotypes makes sample size and study duration particularly important in 
clinical trial design.  However, the relatively low incidence and severe, rapid disease course 
present numerous challenges in running a clinical trial for putative ALS treatments.  As a result, 
many trials were inconclusive due to inadequate sample size, missing controls, short study 
duration, and/or inadequate outcome measures [84]. 
New directions in ALS treatment research include studies regarding gene therapy and 
stem cell transplantation.  Gene therapy has the potential for the direct delivery of treatments to 
the CNS via direct injection or retrograde axonal transport [2].  This technique can be used to 
deliver protective proteins addressing multiple aspects of ALS pathogenesis, or to knock down 
expression of mutant genes with toxic functions [2].  Additionally, stem cell transplantation 
therapy to replace or support degenerating neurons is also being examined [2]. 
1.4 BIOMARKERS FOR ALS  
A biomarker is a biologically produced or modified substance or response that is used as an 
objective indicator of a biological state.  Biomarkers can be used to evaluate the state of normal 
functioning, pathophysiological processes, or clinical responses to therapeutic intervention.  
Types of clinical biomarkers include proteins, non-protein molecules, and measurable results of 
radiologic or physiologic testing.  Clinically, biomarkers are most commonly used for diagnostic, 
surrogate, and prognostic purposes.   
 
 21 
1.4.1 Types of Biomarkers Needed for ALS 
1.4.1.1 Diagnostic Biomarkers 
Diagnostic biomarkers are used to confirm the presence of a specific disease state, or to 
provide supplementary evidence for a particular clinical diagnosis.  An ideal diagnostic 
biomarker has high sensitivity and specificity for the disease, and is present both early in the 
disease process and throughout the disease course.  A marker with 100% sensitivity for a 
disease is present in all individuals in which the disease is present, and a marker with 100% 
specificity is absent in all individuals who do not have the disease.  Therefore, the presence of a 
marker with perfect sensitivity and specificity would be sufficient, on its own, to make a definite 
diagnosis of the disease it signifies.  Additionally, a diagnostic biomarker that is expressed prior 
to disease pathology or early in the disease process is ideal for the early identification of 
affected individuals.    
 Because there is no absolute diagnostic test for ALS, clinical biomarkers are needed to 
improve the speed and accuracy of the diagnostic process.  Currently, clinical disease 
management is hindered by a lengthy diagnostic process that is based heavily on clinical 
criteria.  Because the signs and symptoms that distinguish ALS from related diseases develop 
gradually over the course of disease progression, it often takes a full year or longer to confirm 
an ALS diagnosis.  This delay significantly reduces the window of opportunity for therapeutic 
interventions.  As new drugs that slow or arrest disease progression become available, early 
initiation of treatment will become paramount.  For this reason, new diagnostic tests must be 
developed in order to maximize treatment efficacy for future patients.  A single protein 
biomarker with ideal diagnostic parameters would be sufficient to serve this purpose, but the 
extreme pathophysiologic and phenotypic heterogeneity of ALS indicates that the discovery of a 
single, universal diagnostic biomarker is unlikely.  Alternatively, a panel of multiple protein 
biomarkers with sensitivity for different disease characteristics could serve this purpose, if a set 
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of proteins that exhibit consistent alterations in ALS patients relative to controls can be 
identified.  
1.4.1.2 Surrogate Biomarkers 
Surrogate biomarkers are used to evaluate a biological state or process that cannot be 
measured directly.  Clinically, they are often used to determine the magnitude of disease burden 
at a single point in time and to track longitudinal disease progression.  Additionally, they are 
useful in measuring the therapeutic responses to clinical interventions, and are often used as 
end-points in clinical trials.   
 Surrogate biomarkers currently used for ALS include functional outcome measures, 
electrophysiologic test results, and radiologic test results.  All of these techniques measure 
remote consequences of motor neuron degeneration and may not accurately reflect neuronal 
loss or escalating pathology with temporal fidelity.  Furthermore, the functional measures (which 
are most widely used) are susceptible to multiple confounding variables that are not directly 
dependent on motor neuron degeneration, such as experimenter technique or bias, effort-
dependence, and overall wellness of the patient.  Novel surrogate biomarkers of disease status 
are needed to aid in monitoring disease progression in order to improve the clinical 
management of ALS patients.  Additionally, both disease heterogeneity and several specific 
clinical characteristics of ALS have severely limited the efficiency of past clinical trials.  The 
identification of strong surrogate markers of disease progression and therapeutic response has 
the potential to offset these factors and increase the power of future clinical trials to identify 
beneficial treatments.   
1.4.1.3 Prognostic Biomarkers 
Prognostic biomarkers are used to predict the likelihood of different clinical outcomes for a 
patient, ranging from the development of specific disease characteristics to the total expected 
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survival time.  Clinically, prognostic biomarkers can assist in decisions regarding appropriate 
patient management by predicting the expected disease course.  Prognostic biomarkers are 
also useful in maximizing statistical power in clinical trial design.  They can be used as part of 
the inclusion criteria to identify patients who are likely to survive the length of the trial or to 
exhibit specific characteristics that will maximize trial efficiency.  Additionally, they can be used 
to stratify patients by expected outcome or to balance prognostic factors among experimental 
groups. 
 Several demographic and clinical prognostic factors have been validated for ALS, but 
disease prognosis still cannot be predicted with high accuracy for individual patients [99].  The 
identification of novel protein biomarkers with specific prognostic applications would assist in 
clinical disease management, and give a much needed boost to the efficiency and power of 
clinical drug trials.   
 Overall, the discovery, validation, and application of all three types of clinical biomarkers 
may provide a substantial contribution to the medical management of ALS.  Such biomarkers 
may be key contributors in designing and executing the clinical trials which finally identify 
effective protocols for the treatment of ALS.  Furthermore, they could expedite the diagnostic 
process, allowing for the earlier application of newly developed treatments.  This could further 
increase the effectiveness of treatment protocols and, hopefully, provide significant and 
meaningful clinical improvements for patients with ALS. 
1.4.2 Discovery Strategies for ALS Biomarkers 
Proteomic techniques for the discovery of differentially-expressed proteins utilize various high-
throughput technologies to separate the proteins present in the biological samples and quantify 
differences in protein abundance or post-translational modifications.  Most studies use some 
form of mass spectrometry in conjunction with an additional separation technique, but antibody-
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based microarrays have also been used.  Potential differences identified by these techniques 
require validation by alternate proteomic assays such as immunoblot or enzyme-linked 
immunosorbent assay (ELISA) [37].  
 Feasible sample types for clinical biomarker discovery and measurement in ALS include 
CSF, blood plasma or serum, urine, and saliva.  Urine and saliva are the easiest and safest to 
collect, but are unlikely to contain many disease-relevant changes due to spatial separation 
from the regions of disease pathology.  Plasma and serum are also relatively easy and safe to 
collect by intravenous blood draw, and they contain a rich variety of proteins for evaluation.  
However, high protein concentrations can obscure proteins with low abundance, and relevant 
CNS proteins may have limited entry into the systemic circulation.  CSF is the biofluid that is 
most likely to contain disease-specific biomarkers due to its close proximity to regions of 
neurodegeneration and continuity with fluid in the extracellular spaces of the brain and spinal 
cord.  However, CSF collection by lumbar puncture is more difficult and carries more risks than 
a simple blood draw, and only a limited volume can be collected at a single time.  Overall, CSF 
and plasma/serum show the highest potential for biomarker discovery and, accordingly, are the 
most extensively studied [37]. 
1.4.3 Potential ALS Biomarkers  
To date, approximately 50 proteins have been evaluated for biomarker utility in ALS [37].   
Proteins from multiple functional categories have been evaluated in CSF, plasma, and serum, 
and a sample of the results is given in Table 4.  Many of these studies utilized relatively small 
sample sizes, and were likely underpowered due to the high variability of ALS pathophysiology 
and phenotypes.  Additionally, for proteins evaluated by multiple laboratories, the results 
generated were not always concordant.  Therefore, proteins with the highest potential for 
biomarker application need to be validated by larger studies with new cohorts of patients [37]. 
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Table 4.  Non-exhaustive list of potential protein biomarkers for ALS.  An up arrow (↑) indicates 
that the protein is upregulated in the specified biofluid.  A down arrow (↓) indicates that the 
protein is downregulated in the specified biofluid.  IGF-1 = insulin-like growth factor 1; MCP-1 = 
monocyte chemoattractant protein 1; MMP-9 = matrix metalloproteinase 9; NFH = neurofilament 
heavy chain; NFL = neurofilament light chain; TGF-β1 = transforming growth factor β1; TTR = 
transthyretin; VEGF = vascular endothelial growth factor.  Modified from [37]. 
Functional 
Category 
Example 
Proteins 
CSF Serum Plasma 
Enzymes and 
enzyme 
inhibitors 
Cystatin C ↓ 
  
MMP-9 No change ↑ 
 
SOD ↑ 
 
No change 
Neuron specific 
proteins 
Tau ↑ or No change 
  
NFH ↑ 
  
NFL ↑ 
  
Hormones and 
growth factors 
VEGF ↓ or No change ↑ or No change No change 
Insulin ↓ ↓ 
 
IGF-1 ↓ or No change ↑ or No change 
 
Inflammation 
related proteins 
Caspase-1 ↓ ↑ 
 
MCP-1 ↑ ↑ or No change 
 
TGF-β1 No change No change ↑ 
Other proteins 
Cytochrome C ↓ 
  
Fibronectin 
  
↓ 
TTR ↓ 
  
 
 
 In addition to protein indicators of biological function, the results of radiographic and 
physiologic testing can also serve as clinical biomarkers.  Radiographic techniques currently 
being developed for biomarker applications estimate motor neuron loss by measuring the 
structure or activity of relevant brain and spinal cord regions.  These include magnetic 
resonance imaging (MRI), magnetic resonance spectroscopy (MRS),  diffusion tensor imaging 
(DTI), magnetic resonance voxel-based morphometry (MRM), positron emission tomography 
(PET), and functional MRI (fMRI) [100, 101].  Neurophysiologic techniques include 
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measurements of cortical excitability, which is increased in ALS and may correlate with UMN 
loss, and motor unit number estimation (MUNE), which quantifies peripheral effects of LMN loss 
[100, 102].   These techniques are primarily useful for monitoring disease progression, but 
potential diagnostic and prognostic uses have also been identified.   
1.5 CYSTATIN C 
Cystatin C is a cysteine protease inhibitor that is expressed by all nucleated cells, and is present 
in nearly all human biofluids at physiologic concentrations [103, 104].  It is of particular interest 
as a potential ALS biomarker because it is concentrated within the CSF, it appears to be 
differentially abundant in the CSF of ALS patients versus controls, and it has both 
neuroprotective and neurotoxic physiologic properties.  Additionally, cystatin C is one of three 
known protein components of Bunina bodies, which are small intraneuronal inclusions specific 
to ALS [23]. 
1.5.1 Production and Structure 
Cystatin C is synthesized as a 146 amino acid protein with a 26 amino acid N-terminal signaling 
sequence that functions in targeting the protein for processing and secretion.  The signaling 
sequence is cleaved in the endoplasmic reticulum, and the remainder of the protein is 
processed through the golgi apparatus and secretory pathway.  The mature 120 amino acid 
protein weighs 13.3 kDa, is active as a monomer, and is inactivated by dimerization.  The three-
dimensional structure of the mature protein includes a central α-helix flanked by a five-stranded 
antiparallel β-sheet, with two disulfide bonds near the carboxy-terminus (Figure 2) [105].  The 
binding site for papain-like cysteine proteases (C1 family) and calpains (C2 family), which 
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include the majority of protein targets, is formed by two β-hairpin loops and the N-terminal 
region of the protein [106].  The binding site for legumain-like cysteine proteases (C13 family) 
appears to be on the opposite surface of the protein, between the α-helix and the main β-sheet 
[107]. 
 
 
 
 
Figure 2.  Structures of the monomeric and dimeric forms of human cystatin C.  The monomeric 
form (A) is active and contains a binding site for papain-like cysteine proteases and calpains, 
which is composed of the L1 and L2 β-hairpin loops and the N-terminus of the protein.  There is 
also a proposed binding site for legumain-like cysteine proteases on the opposite side of the 
protein, near the AS region.  The dimeric form (B) is inactive against C1 and C2 cysteine 
proteases, and is formed by three-dimensional domain swapping between two cystatin C 
molecules (shown in blue and green).  AS = appending structure; C = carboxy-terminus; L1 = β-
hairpin loop 1; L2 = β-hairpin loop 2; N = amino-terminus.  Modified from [105]. 
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1.5.2 General Function  
Cystatin C strongly and reversibly inhibits a wide variety of cysteine proteases including those of 
families C1 (plant-derived papain and mammalian cathepsins B, H, K, L, and S), C2 (calpains), 
and C13 (mammalian legumain) [103, 107-109].  The activity of cystatin C against C1 cysteine 
proteases, but not C13 proteins, is inactivated by dimerization.  Under acidic conditions, cystatin 
C can also oligomerize to form amyloid fibers [103].  Finally, cystatin C can also be inactivated 
through proteolytic degradation by cathepsin D and elastase [110, 111]. 
 The physiological functions of cystatin C are not well understood, but it is likely to have 
multiple roles in biological processes involving proteolysis.  Proteolytic enzymes such as 
cysteine proteases irreversibly cleave peptide bonds to aid in substrate protein maturation, 
modulation, and destruction.  Cystatin C and other protease inhibitors regulate these processes 
to maintain healthy physiologic functioning [112].   
 Cystatin C is processed through the secretory pathway and primarily functions in the 
extracellular fluid, but it may also act on its target proteases in other regions where they localize.  
For example, cystatin C has been shown to localize to endocytic cellular compartments and 
inhibit cathepsins within the lysosomal system [113].  Cathepsins generally localize to 
lysosomes and regulate proteolytic pathways in acidic cellular compartments [112].  However, 
they have also been shown to function in the cytosol, the nucleus, secretory vesicles, and the 
extracellular fluid [112].  Calpains are primarily localized to the cytoplasm, but nuclear and 
extracellular activities have been documented [114].  Finally, legumains have a primarily 
lysosomal distribution and are thought to be involved in antigen presentation [107].  Specific 
physiological roles hypothesized for cystatin C include regulatory roles in bone resorption, 
extracellular matrix remodeling, inflammatory responses, cell proliferation, and CNS 
development [103, 109, 115].   
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1.5.3 Biomarker Usage in the Periphery 
Cystatin C has been extensively studied as a marker of renal function because its rate of 
production in the periphery is relatively constant and its plasma levels are mainly determined by 
glomerular filtration [104].  However, peripheral cystatin C production has been shown to vary 
slightly by age, gender, muscle mass, steroid hormone levels, levels of inflammation, and the 
presence of neoplasia [104].   
 Increased plasma cystatin C has also been shown to be an independent prognostic 
factor for cardiovascular disease, and to be directly correlated with the risk of a second 
cardiovascular accident following an initial cardiovascular event [116].  Additionally, in patients 
with cardiovascular disease, elevated plasma cystatin C levels are predictive of mortality from 
all causes via a direct, linear relationship [104, 117].  The reasons that plasma cystatin C is 
increased in this patient population are unknown, but are hypothesized to relate to morphologic 
and functional cardiac abnormalities, or exercise intolerance [118-120]. 
1.5.4 Function Within the CNS 
Cystatin C is highly expressed by the choroid plexus [121] and is the predominant cysteine 
protease inhibitor in the CSF [103].  The function of cystatin C within the CNS under physiologic 
conditions has not been elucidated, but it appears to play multiple roles in CNS trauma and 
neurodegeneration.  Cystatin C expression is upregulated following several types of CNS 
damage including ischemia, axonal injury, status epilepticus, oxidative stress, 6-OHDA-induced 
lesions, and several neurodegenerative disorders [109, 122-127].  However, it is unclear 
whether this is a pathway contributing to cell death, or alternatively, a protective response.     
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1.5.5 Biomarker Usage in the CNS 
Differential concentration of cystatin C within the CSF has been reported in several 
neurodegenerative diseases other than ALS, including Creutzfeldt-Jakob disease [128], 
Alzheimer's disease [129], and frontotemporal dementia [130], Guillain-Barré syndrome [131], 
chronic inflammatory demyelinating polyneuropathy [131], and multiple sclerosis [131].  
However, many of these results have not been replicated [132-134], and cystatin C has not yet 
been validated as a diagnostic biomarker for any of these disorders. 
 In patients with Alzheimer's disease, CSF cystatin C levels have also been found to 
strongly and directly correlate with both total tau and phosphorylated tau, indicating potential 
utility of cystatin C for use as a surrogate marker of tau load [132].  Additionally, CSF cystatin C 
appears to be elevated in inflammatory CNS conditions, suggesting that it may function as a 
non-specific marker of CNS inflammation [135]. 
1.5.6 Alterations in ALS 
Our lab has used surface-enhanced laser desorption/ionization time of flight mass spectrometry 
(SELDI-TOF-MS) to identify potential protein biomarkers that are differentially expressed in the 
CSF of ALS patients relative to controls [136].  We recently found cystatin C to be significantly 
less abundant in the CSF of ALS patients relative to mixed healthy/neurological disease controls 
[136], and a second group subsequently reported similar mass spectrometry findings relative to 
healthy controls [137].  We validated these findings with a larger SELDI-TOF-MS study, which 
confirmed that CSF cystatin C in ALS patients exhibits reduced abundance relative to both 
healthy controls and mixed neurological controls [138].  Attempts to further validate these 
differences with immunoassays have been variable.  One small study reported a significant 
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reduction in CSF cystatin C concentration in ALS patients relative to individuals with 
polyneuropathy [139], but a second study found no difference relative to normal controls [134].   
 Cystatin C is also been linked to ALS histopathologically, as it localizes to Bunina bodies 
[23] and demonstrates an altered immunohistochemical staining pattern in motor neurons.  In 
post-mortem tissue from individuals without ALS, cystatin C immunostaining in motor neurons is 
intense, and is distributed in an even or granular throughout the cytoplasm.  In contrast, motor 
neurons in ALS patients exhibit faint cytoplasmic staining with occasional immunopositive 
Bunina bodies [23, 140-142].  Astrocytes in the spinal gray matter and white matter also exhibit 
significant reductions in cystatin C immunoreactivity in ALS patients relative to controls.  
Cystatin C alterations are also observed in transgenic rodent models of ALS, and include 
increased protein expression and cytoplasmic staining that was granular rather than diffuse 
[143].  
 These findings suggest that cystatin C may be differentially regulated in ALS patients 
relative to controls and indicate potential for utility as a diagnostic biomarker. 
1.5.7 Effect on Neurons and Potential Role in ALS Pathogenesis 
The effects of cystatin C on motor neurons have not been previously examined, but it appears 
to have both neurotoxic and neuroprotective properties, depending on the context. Evidence for 
a neurotoxic role has been presented by Nagai et al., who found that the injection of cystatin C 
into the rat hippocampus in vivo induces neuronal cell death in the dentate gyrus [144].  In a 
subsequent study, this group also demonstrated that the addition of cystatin C to human 
neuronal cell cultures results in increased neuronal death, number of TUNEL positive cells, and 
caspase-3 activation [145].  These findings suggest that cystatin C may play a role in the 
induction of neuronal apoptosis.  Two additional characteristics of cystatin C which could 
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contribute to its neurotoxic properties include the ability to form intracellular aggregates [146], 
and its putative immunomodulatory functions [147].   
 Conversely, Xu et al. have reported that the administration of exogenous cystatin C 
partially rescues nigral dopamine neurons following 6-OHDA-induced lesions in vivo [127].  This 
neuroprotective effect of cystatin C was also observed in fetal mesencephalic cultures exposed 
to 6-OHDA [127].  Furthermore, overexpression of cystatin C in rat pheochromocytoma (PC12) 
cells improves survival following several types of oxidative stress [148].  The neuroprotective 
properties of cystatin C may arise, in part, from its inhibition of cathepsins B and L, which can 
induce neuronal apoptosis both in vitro and in vivo [149, 150].  Together, these findings suggest 
that altered levels of cystatin C have the potential to play a role in neurodegeneration in ALS. 
1.6 BLOOD-CNS BARRIER DISRUPTION IN ALS 
1.6.1 The Blood-CNS Barrier 
The CNS is separated from the circulatory system and the periphery by a group of selectively 
permeable barriers including the blood-brain barrier (BBB), the blood-CSF barrier (BCSFB), and 
the blood-spinal cord barrier (BSCB).  Together, these structures can be collectively referred to 
as the blood-CNS barrier (BCNSB).  The function of the BCNSB is to protect the sensitive CNS 
from harsh or damaging components of the periphery, and also to maintain homeostatic 
composition of the CNS interstitial fluid by regulating the levels of ions and metabolic substrates 
[151]. 
The BCNSB is formed by tight junctions between blood vessel endothelial cells, 
astrocytic foot processes that surround the endothelial monolayer, pericytes located between 
the astrocytes and the endothelial cells, and a basement membrane that surrounds the 
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endothelial cells and pericytes [151].  The BBB and BSCB are formed by these elements within 
the capillary network of the brain and spinal cord, respectively.  The BCSFB is located at the 
border between the choroid plexus and the ventricular system, and is formed by choroid plexus 
epithelial cells, which also carry out extensive secretory functions and produce CSF [152, 153].  
All of the components of the BCNSB also contain numerous active transport systems, which 
carry essential materials and nutrients into the CNS and shuttle potentially damaging 
substances from the CNS into the peripheral compartment [154]. 
1.6.2 BCNSB Disruption in Neurodegenerative Disease 
Disruptions of BCNSB function can allow the passage of inflammatory cells and water soluble 
substances into the CNS, often resulting in edema and CNS damage [154].  This process is 
thought to play an important role in the pathogenesis of several neurodegenerative disorders, 
and can participate in disease initiation and/or disease progression [151, 155].  Implicated 
diseases include multiple sclerosis [151], Alzheimer's disease [156], Parkinson’s disease [157], 
and Huntington’s disease [158]. 
1.6.3 Evidence for BCNSB Disruption in ALS  
All three components of the BCNSB are suspected to be disrupted in ALS [159, 160].  This idea 
was first suggested by the observation that CSF albumin/serum albumin ratios are often 
increased in ALS patients [161-163], presumably due to the leakage of serum albumin into the 
CNS.  This finding was supported by reports of endothelial cell activation/injury and the 
downregulation of tight junction protein expression in the post-mortem spinal cord in some ALS 
patients [164-166].  These findings indicate that BCNSB compromise may occur in some 
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individuals during the symptomatic phase of the disease.  However, specifics regarding the 
initiation and temporal characteristics of these events remain unknown. 
Dysfunction of the BBB and BSCB has been much more thoroughly characterized in 
transgenic rodent models of SOD1-mediated FALS.  These animals exhibit downregulation of 
tight junction proteins, concomitant vascular microhemorrhages, and leakage of neurotoxic, 
hemoglobin-derived products, all at close proximity to motor neurons and before motor neuron 
degeneration begins [166-168].  Additionally, endothelial cell damage and vascular leakage in 
the brain and spinal cord are observed throughout the symptomatic course of the disease [153, 
167-169].  The early onset and spatial localization of these findings suggest that BBB and BSCB 
damage may be involved in disease initiation and play a significant role in disease progression 
in transgenic rodent models of FALS.  Further research is needed to characterize BCNSB 
disruption in both sporadic and familial human disease, and to determine its relationship to 
disease pathogenesis.   
1.6.4 Potential Role of BCNSB Disruption in ALS Pathogenesis 
Damage or disruption of the BBB or the BSCB in the vicinity of motor neurons could potentially 
be a primary component of disease pathogenesis or a secondary effect of advanced disease 
progression.  Once initiated, this process may contribute to motor neuron damage and disease 
progression in a variety of ways.  First, the entry of plasma proteins into the CNS causes edema 
due to osmotic stress.  Inflammatory cells can also gain entry into the normally immuno-
priviledged CNS and contribute to neuroinflammation and associated tissue damage.  
Additionally, neurotoxic blood-derived proteins can leak into the CNS and affect tissues near the 
point of entry or at distant CNS locations.  Hemoglobin is one of many blood-derived proteins 
with the potential to damage motor neurons following BCNSB compromise [170]. 
 35 
1.6.5 Potential Effects of BCNSB Disruption on Biomarker Distribution 
Most disease-specific biomarkers for ALS are likely to be generated within the CNS, as this is 
the region where the majority of primary ALS pathology occurs.  Because it is not possible to 
safely biopsy CNS tissue, the closest biological material available for biomarker collection is 
CSF, which is continuous with the extracellular fluid of the CNS.  For this reason, CSF probably 
holds the highest potential for the identification of biomarkers that represent primary 
pathological processes.  However, CSF is somewhat difficult to collect, and the collection 
procedures impose significant risks for patients. 
The peripheral circulation is separated from the CSF and extracellular fluid of the CNS 
by the BCNSB, but many CNS proteins are returned to the peripheral compartment via 
reabsorption by the arachnoid villi in the superior saggital sinus or through the lymphatic 
system.  However, the number of relevant proteins that enter the peripheral circulation, and the 
subsequent concentration of these proteins in the plasma are both likely to be significantly lower 
than in the CSF.  Attempts to measure CNS-relevant proteins in the plasma are further 
complicated by the greater protein concentration and diversity of extraneous proteins in this 
biofluid.   
The presence of BCNSB damage in neurodegenerative disorders such as ALS would 
provide the possibility of rapid protein exchange between the CNS and peripheral 
compartments, potentially changing the distribution of disease-relevant proteins.  If such 
proteins are generated at a high level in the region of BBB or BSCB disruption, it is possible that 
they could enter the peripheral blood stream at high enough concentrations to be easily 
detected through a simple blood draw.  This procedure is easier and safer than CSF collection, 
and could potentially be used as a screening test for high risk populations, if the timing and 
duration of BBB/BSCB disruption is appropriate.  Conversely, the leakage of non-specific blood-
derived proteins into the CSF would likely complicate biomarker evaluation in that fluid. 
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Finally, the presence of a protein in the CNS that is normally excluded by functional 
blood-CNS barriers could, itself, serve as a biomarker of BCNSB disruption.  For example, red 
blood cells (RBCs) are fully excluded from the CNS under physiologic conditions.  However, 
BCNSB damage can allow the passage of RBCs into the extracellular space or directly into the 
CSF.  Lysis of these cells results in the release of free hemoglobin proteins, which can be 
measured in the CSF as a marker of BCNSB disruption. 
1.7 PURPOSE OF RESEARCH 
The clinical management of ALS is severely limited by both a lack of disease-related biomarkers 
and the absence of effective long-term treatments.  The identification and characterization of 
novel biomarkers holds the potential to improve diagnostic protocols, expand our understanding 
of disease pathogenesis, and expedite the development of new therapeutic agents. 
Our lab has identified several proteins that appear to be differentially abundant in the 
CSF of ALS patients relative to controls.  These proteins may have utility as measurable 
biomarkers of disease characteristics, and may also play active roles in disease development or 
progression.  The purpose of this study was to evaluate two such proteins for clinical biomarker 
utility and insight into disease pathogenesis.  First, cystatin C was comprehensively evaluated 
for utility as a diagnostic, surrogate, and prognostic biomarker in ALS. The activity of cystatin C 
within the CSF was also assessed to clarify its potential roles in disease progression.  Secondly, 
the expression patterns of CSF hemoglobin were characterized in ALS patients and controls in 
order to confirm qualitative observations of a potential difference that carries significant 
implications regarding disease pathogenesis.  
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2.0  CYSTATIN C AS A BIOMARKER FOR AMYOTROPHIC LATERAL SCLEROSIS 
2.1 ABSTRACT   
Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease characterized by progressive 
motor neuron degeneration.  Clinical disease management is hindered by a lengthy diagnostic 
process and the absence of effective treatments.  Reliable panels of diagnostic, surrogate, and 
prognostic biomarkers are needed to accelerate disease diagnosis and expedite drug 
development.  The cysteine protease inhibitor cystatin C has recently gained interest as a 
candidate diagnostic biomarker for ALS, but further studies are required to fully characterize its 
biomarker utility.  I used quantitative enzyme-linked immunosorbent assay (ELISA) to assess 
initial and longitudinal cerebrospinal fluid (CSF) and plasma cystatin C levels in 104 ALS 
patients and controls.  Cystatin C levels in ALS patients were significantly elevated in plasma 
and reduced in CSF compared to healthy controls, but did not differ significantly from 
neurological disease controls.  In addition, the direction of longitudinal change in CSF cystatin C 
levels correlated to the rate of ALS disease progression, and initial CSF cystatin C levels were 
predictive of patient survival, suggesting that cystatin C may function as a surrogate marker of 
disease progression and survival.  These data verify prior results for reduced cystatin C levels in 
the CSF of ALS patients, identify increased cystatin C levels in the plasma of ALS patients, and 
reveal correlations between CSF cystatin C levels and both ALS disease progression and 
patient survival.   
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2.2 INTRODUCTION 
Amyotrophic lateral sclerosis (ALS) is a fatal neuromuscular disease that affects approximately 
1.5 to 2.5 per 100,000 individuals of all races and ethnicities throughout the world [171].  ALS 
patients typically undergo rapid disease progression, though a subset exhibits slow progression 
and may live over a decade from symptom onset [172, 173].  Unfortunately, there is only one 
drug currently approved by the FDA to treat ALS, and this therapy increases life span by just 
two to three months on average [85].  Clinical disease management is also hindered by an often 
lengthy diagnostic process based predominately on clinical criteria [100].  As new drugs that 
slow or arrest disease progression become available, early initiation of treatment will become 
paramount.  For this reason, diagnostic biomarkers for ALS must be identified and validated to 
maximize treatment efficacy for future patients.  Several individual panels of CSF proteins have 
shown promise as candidate biomarkers, but none have been fully validated or integrated into 
clinical practice [136, 137, 174]. 
Biomarkers also hold promise to monitor disease progression and to stratify patient 
populations for use in clinical trials.  One reason new drug therapies have not been successfully 
translated from ALS model systems to humans is ALS disease heterogeneity [175].  Biomarkers 
that monitor disease progression would aid in the design and execution of human clinical trials 
and would provide novel targets for future drug therapies; prognostic biomarkers that predict 
patient survival would also aid in the design of clinical trials.  While there are several validated 
demographic and clinical prognostic factors for ALS, disease prognosis cannot currently be 
predicted with high accuracy within individual patients [99].  Ultimately, surrogate biomarkers of 
disease progression would provide a means to more rapidly monitor drug efficacy in clinical 
trials [100, 175-177].  Therefore, the search for biomarkers that fit these functional 
characteristics represents a key challenge toward improving drug therapies and clinical 
management for ALS. 
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One protein that has shown potential for ALS diagnostic utility is cystatin C, a widely 
expressed cysteine protease inhibitor that is approximately five times more abundant in CSF 
than in plasma [178].  Cystatin C is processed through the secretory pathway, and, in its active 
monomeric form, inhibits a wide variety of cysteine proteases including cathepsins B, H, L, and 
S, calpains and caspases [103].  Cystatin C is also linked to ALS histopathologically, as it is one 
of only three known proteins that localize to Bunina bodies, which are small intraneuronal 
inclusions specific to ALS [23]. 
Two prior surface-enhanced laser desorption/ionization time of flight mass spectrometry 
(SELDI-TOF-MS) studies reported significant decreases in CSF cystatin C levels in ALS 
patients relative to healthy controls [137] and mixed healthy/neurological disease controls [136].  
A recent study using small numbers of test subjects reported a significant reduction in CSF 
cystatin C concentration in ALS patients relative to individuals with polyneuropathy, as 
measured by ELISA [139].  However, a second study failed to find a difference in CSF cystatin 
C between ALS patients and healthy controls [134].  While the majority of these prior studies are 
encouraging, a larger study with a more comprehensive group of ALS-mimic disease controls is 
required in order to verify prior results and determine if CSF cystatin C levels represent a 
candidate diagnostic biomarker for ALS.   
The objective of this study was to use quantitative ELISA to further evaluate the utility of 
cystatin C as a biomarker for ALS using a large subject population.  I evaluated cystatin C in 
both CSF and plasma as a candidate diagnostic biomarker, and correlated levels to individual 
ALS patient survival and disease progression.  I verified that cystatin C protein levels are 
reduced in the CSF of ALS patients and discovered that cystatin C levels are increased in the 
plasma of ALS patients.  However, cystatin C levels in either biofluid were not highly predictive 
of ALS.  I also determined that CSF cystatin C levels correlate to ALS patient survival, and 
change during disease progression. 
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2.3 MATERIALS AND METHODS 
2.3.1 Sample Collection 
This study was approved by the institutional review board (IRB) at the University of Pittsburgh, 
and written informed consent was obtained from all participating subjects.  ALS subjects were 
diagnosed by experienced neurologists specialized in motor neuron disease, using revised El 
Escorial criteria [19].  CSF and plasma samples were collected at the same office visit every 
four to six months from 44 ALS patients (2-8 draws), and either once or twice (1.5-2 years apart) 
from 35 non-neurological healthy controls (HC) and 25 neurological disease controls (DC).  The 
total enrollment of 104 patients provided adequate power for this study as a pre-study power 
analysis using projected effect sizes based on previous mass spectrometry findings [138] 
concluded that a total enrollment of 96 patients was required to identify pairwise differences 
between ALS patients and both HC and DC groups for both measures of cystatin C.  I did not 
control for potential confounding variables such as socioeconomic status, nutrition, 
environmental exposures, etc. between diagnostic groups.  The median time from symptom 
onset to first draw for ALS patients was 468 days.  Clinical parameters used to monitor ALS 
disease progression included the ALS functional rating scale (ALSFRS-R), manual muscle 
strength tests (MMT), and forced vital capacity (FVC) [179-181]. 
The disease control group included six patients with multiple sclerosis, one with bilateral 
facial palsies, one with neurosarcoidosis, one with viral encephalitis, one with CNS lymphoma, 
one with brain metastases, one with pseudotumor cerebri, one with a seizure disorder, one with 
complicated migraine, one with paresthesis and possible myelopathy, one with a probable 
conversion disorder, and nine with neurological diseases that can clinically resemble ALS at 
presentation.  This ALS-mimic disease subgroup included two patients with primary lateral 
sclerosis (PLS), two with chronic inflammatory demyelinating polyneuropathy (CIDP), two with 
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progressive muscular atrophy, one with spinocerebellar ataxia, one with small fiber neuropathy, 
and one with idiopathic sensorimotor polyneuropathy.   
CSF samples were obtained by lumbar puncture, immediately centrifuged at 450 g for 
five minutes at 4˚C to remove cells and debris, aliquoted, and then frozen at -80˚C.  Intravenous 
blood samples were collected in EDTA containing tubes, inverted to mix, and centrifuged at 
1,733 g for 10 min at 4˚C.  The plasma was then decanted, aliquoted, and frozen at -80˚C.  CSF 
and plasma were aliquoted into small volumes for single use in experiments in order to eliminate 
any freeze/thaw effects.  Samples of either biofluid were thawed on ice immediately prior to use.   
2.3.2 BCA Protein Assay 
Total protein concentrations in CSF and plasma samples were measured using a BCA Protein 
Assay Kit (Pierce, location), according to the manufacturer's instructions.  Briefly, biofluid 
samples were diluted by 1:20 in prepared BCA Working Reagent and incubated at 37°C for 30 
min.  Samples were allowed to cool to room temperature, and then absorbance was measured 
at 562 nm using a plate reader.  Final protein concentrations were calculated using a standard 
curve generated by the absorbance of serially diluted BSA Albumin Standards.  All samples 
were measured in duplicate in two separate experiments, and the results were averaged.   
2.3.3 Cystatin C ELISA 
CSF and plasma samples from individual patients were assigned to random 96-well plate 
positions, and evaluated in duplicate wells for each ELISA.  All samples were independently 
assayed at least twice.  For all experiments, I used a human cystatin C sandwich ELISA kit 
(Biovendor, Candler, NC), according to the manufacturer’s instructions.  Briefly, diluted CSF and 
plasma samples (1:2000 and 1:400, respectively, in dilution buffer) were applied to antibody 
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pre-coated ELISA plates for 30 min with gentle agitation.  The wells were washed thoroughly 
and then the secondary antibody conjugate solution was applied for 30 min with gentle agitation.  
After a second wash, the 3,3’,5,5’ Tetramethylbenzidine substrate solution (Biovendor, Candler, 
NC) was applied for 10 min, color development was stopped with an acidic stop solution, and 
the optical density (OD) was measured at 450 nm using a plate reader.   
2.3.4 Statistics 
All statistics were carried out using SPSS software, unless otherwise noted.  Data normality was 
assessed by the Kolmogorov-Smirnova and Shapiro-Wilk tests, and normality was only 
assumed when indicated by both tests.  All calculated p-values were two-tailed, and the 
significance level was set at p<0.05. 
2.3.4.1 Comparison of Total Protein Levels 
Because total protein levels were non-normally distributed in both CSF and plasma, differences 
among experimental group medians were identified using Kruskal-Wallis one-way ANOVA.  
Mann-Whitney-Wilcoxon tests were then used to assess pairwise differences between medians. 
2.3.4.2 Data Processing  
For each ELISA plate, a standard curve was generated by plotting the logarithm of the cystatin 
C concentration against the logit log of the adjusted OD (divided by a constant to produce a 
data range between zero and one, as required for the logit logarithm function).  This procedure 
produced a linear standard curve, which was then used to calculate sample cystatin C 
concentration from sample OD for each ELISA run.  For the nine CSF and 13 plasma samples 
that were assayed more than twice, outlier runs (three each for CSF and plasma) were identified 
on the basis of high coefficients of variation (CV) with the other data for the same sample, and 
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were dropped from further analyses.  The remaining runs for each sample were averaged to 
determine the absolute cystatin C concentration, or “total cystatin C,” for each sample.  Sample 
cystatin C concentrations were then normalized to the total protein concentrations to determine 
the percent of total biofluid protein accounted for by cystatin C, or “percent cystatin C.” 
2.3.4.3 Assessment of ELISA Performance 
I used Microsoft Excel to calculate standard curve regression lines and their coefficients of 
determination (R2), which were then converted into correlation coefficients (R).  The R values for 
all 22 ELISA plates were then averaged.   
All coefficients of variation were calculated according to the following formula: 
CV = data standard deviation / data mean * 100 
Intra-assay CVs were calculated for the two optical density readings for each sample on 
each plate.  The individual CVs for all sample-runs were then averaged to determine the overall 
intra-assay CV.  Inter-assay CVs were determined for each sample using the final cystatin C 
concentrations calculated for each sample-run.  The CVs for all samples were then averaged to 
determine the overall inter-assay CV. 
2.3.4.4 Assessment of Diagnostic Biomarker Utility 
For the analyses of diagnostic utility, I included only the initial CSF and plasma samples 
collected from each patient, representing the time point closest to symptom onset.  In both 
biofluids, total and percent cystatin C were both non-normally distributed in some diagnostic 
groups. Differences between group and subgroup means were identified using the SPSS 
generalized linear model, with diagnosis and sex as factors in the model and age at draw as a 
covariate.  This model was subsequently used to calculate and compare the estimated marginal 
group means, in order to determine which pairwise differences among the levels of each factor 
were responsible for the significant main effects.  
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2.3.4.5 Assessment of Longitudinal Change in Cystatin C 
The relationship between first-draw cystatin C levels and the length of time from symptom onset 
was assessed by linear regression using GraphPad Prism 5.0 software (GraphPad Software 
Inc, La Jolla, CA).  For this analysis, the “time from symptom onset” data were transformed by 
the natural logarithm (Ln) in order to achieve normality as required by the selected statistical 
test.   
 The effect of time on longitudinal cystatin C levels in ALS patients with multiple biofluid 
draws was assessed with SPSS software, using the general linear model for repeated 
measures.  The model was applied for all patients combined and for patient subgroups sorted 
by progression speed.  Fast progressors were defined as patients exhibiting above average 
rates of ALSFRS decline (median: 0.77 units/month [182]) or MMT decline (mean: drop of 
1%/month [181]), and slow progressors were defined as patients exhibiting smaller than 
average longitudinal decreases in both of these clinical progression measures.     
The longitudinal relationship between cystatin C levels and clinical disease progression 
in individual patients was assessed by nonparametric correlation analysis (using GraphPad 
Prism 5.0) because some of the data were non-normally distributed.  The Spearman's rank 
correlation coefficient (r) was calculated and the permutation test was applied to determine if r 
was significantly different from zero. 
2.3.4.6 Assessment of Prognostic Biomarker Utility  
The relationship between first-draw cystatin C levels and post-draw survival time (for deceased 
patients only) was assessed by Spearman correlation analysis (GraphPad Prism 5.0).  The 
prognostic utility of CSF cystatin C was further explored by generating Kaplan-Meier survival 
curves for patients falling above or below several cut-off values of cystatin C.  SPSS software 
was used to calculate the p-values for differential survival time by three different methods: the 
Log Rank (Mantel-Cox), Breslow (Generalized Wilcoxon), and Tarone-Ware tests.  
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2.4 RESULTS 
Longitudinal CSF and plasma samples were collected from 104 ALS and control subjects (Table 
5) and then absolute cystatin C concentrations were evaluated by ELISA and the total sample 
protein concentrations were measured by BCA protein assay.  I then assessed the biomarker 
utility of two separate measures of cystatin C:  (1) the absolute cystatin C concentrations or 
“total cystatin C” and (2) the “percent cystatin C,” in which the absolute cystatin C 
concentrations were normalized to the total sample protein concentrations to determine the 
percent of total biofluid protein accounted for by cystatin C.  Several clinical measures of 
disease progression were also collected at the time of each biofluid draw (see Section 2.3.1).   
 
Table 5.  Clinical characteristics of all study participants.  MS = multiple sclerosis; PLS = 
primary lateral sclerosis; CIDP = chronic inflammatory demyelinating polyneuropathy; PMA = 
progressive muscular atrophy; SA = spinocerebellar ataxia; NA = not applicable. 
 ALS (n=44) 
Healthy 
controls (n=35) 
All Disease 
Controls (n=25) 
Mimic Disease 
Controls (n=9) 
Sex 
(male/female) 
31/13 13/22 13/12 7/2 
Age at first draw 
± SD (years) 
54.8 ± 13.5 46.8 ± 15.6 47.9 ± 15.4 57.2 ± 11.8 
Relevant 
subgroups 
35 limb onset, 5 
bulbar onset, 4 
mixed/other 
onset 
NA 
9 ALS mimics, 6 
MS, 10 other 
2 PLS, 2 CIDP, 
2 PMA, 1 SA, 1 
small fiber 
neuropathy,  1 
idiopathic 
sensorimotor 
polyneuropathy 
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2.4.1 Total Protein Concentration in CSF and plasma  
Kruskal-Wallis one-way ANOVA revealed a significant difference in the experimental group 
medians for CSF (p=0.001), but not plasma (p=0.106).  Post-hoc Mann-Whitney-Wilcoxon tests 
revealed that CSF total protein levels were significantly elevated in both ALS patients and 
neurological disease controls compared to healthy controls (Table 6).  However, there was no 
difference in total protein levels between ALS patients and neurological disease controls.   
 
Table 6.  First-draw total protein concentration in CSF and plasma. 
CSF total protein (ug/ml) Plasma total protein (ug/ml) 
Diagnosis N Median ± SD Diagnosis N Median ± SD 
ALS 44 835 ± 180* ALS 43 77325 ± 6912 
DC 25 798 ± 299** DC 11 77700 ± 7264 
HC 35 710 ± 110 HC 31 79750 ± 4535 
 
*two-tailed p<0.001 compared to HC; **two-tailed p=0.030 compared to HC. 
2.4.2 ELISA Performance 
The data processing method used produced linear standard curves for each ELISA plate, with a 
mean correlation coefficient (R) of 0.9979.  Sample mean ODs all fell within the standard curve 
mean OD range for the corresponding plate, except for two CSF samples, which each produced 
ODs at the lower end of the standard OD range for one run and just below the range for the 
replicate run.  Finally, both inter- and intra-assay CVs fell within acceptable limits (Table 7).   
 
Table 7.  Assay variability for ELISA assessment of CSF and plasma cystatin C concentration. 
  CSF Plasma 
Mean Inter-assay CV 24.5 17.9 
Mean Intra-assay CV 5.6 5.0 
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2.4.3 Diagnostic Biomarker Assessment 
In order to assess the diagnostic utility of cystatin C, I first compared the mean first-draw 
cystatin C levels among ALS patients, neurological disease controls, and healthy controls.  A 
generalized linear model was used to estimate the mean total and percent cystatin C for each 
diagnostic category, with both gender and age included as co-factors in the model.  This 
statistical design controls for between-group differences in each co-factor when generating 
estimated means.  Therefore, the differences in age and gender among the diagnostic groups 
should not have affected the results, even in the case that cystatin C varies with these factors.  I 
found that the estimated means for both measures of cystatin C were lower in ALS patients than 
in disease controls and healthy controls, similar to prior studies (Table 8).  However, a test of 
the model’s main effects revealed that only percent cystatin C differed significantly by disease 
diagnosis, while total cystatin C levels were not significantly different across diagnostic groups. 
Neither measure of cystatin C differed significantly by age or gender.  In a post-hoc pairwise 
comparison of diagnostic groups, percent cystatin C was found to be significantly lower in CSF 
of both ALS patients and disease controls relative to healthy controls, but there was no 
statistical difference between cystatin C levels in ALS patients and disease controls.   
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Table 8.  CSF main group results for total and percent cystatin C.  Percent cystatin C differed 
significantly by diagnostic category and was significantly reduced in both ALS patients and 
disease controls relative to healthy controls.  ALS = all ALS patients; DC = all neurological 
disease controls; HC = healthy controls.   
 Total Cystatin C Percent Cystatin C 
 Mean (ug/ml) ± S.E.M. Mean (%)  ± S.E.M. 
ALS (n=44) 3.32 ± .19 0.40 ± 0.02 
DC (n=25) 3.61 ± .26 0.45 ± 0.03 
HC (n=35) 4.00 ± .25 0.54 ± 0.03 
Significance of Model Main Effects (p-values) 
Diagnosis 0.109 0.002* 
Gender 0.400 0.740 
Age at Draw 0.367 0.672 
Pairwise Comparisons by Diagnosis (p-values) 
ALS vs. DC 0.384 0.259 
ALS vs. HC 0.038* 0.001* 
DC vs. HC 0.277 0.034* 
 
*indicates statistical significance at p<0.05. 
 
 Next, I repeated these statistical analyses using data from specific patient subgroups, in 
order to determine if either measure of CSF cystatin C can be used to differentiate ALS patients 
from disease controls in specific patient subpopulations.  First, I created a subcategory of 
disease controls comprised of patients with neurological diseases that more closely resemble 
ALS at presentation.  Using this group of ALS mimics in the statistical model, the patterns of 
overall and between-group statistical differences remained the same (Table 9).  However, the p-
values were reduced for the ALS vs. mimic disease control subgroup comparison (Table 9, 
“ALS vs. DC”) relative to the ALS vs. all disease control subgroup comparison (Table 8, “ALS 
vs. DC”) suggesting a stronger trend toward statistical significance when cystatin C is used to 
differentiate ALS patients from this more clinically-relevant control group.   
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Table 9.  CSF main group results, using mimic disease controls.  Percent cystatin C differed 
significantly by diagnostic category and was significantly reduced in ALS patients relative to 
healthy controls.  The diagnostic potential of both measures of cystatin C, as implied by the pair-
wise differences (p-values) between ALS patients and disease controls, was improved when 
comparing ALS to mimic DC rather than all DC (Table 8).  ALS = all ALS patients; HC = healthy 
controls; mDC = mimic disease controls.   
 Total Cystatin C Percent Cystatin C 
 Mean (ug/ml) ± S.E.M. Mean (%)  ± S.E.M. 
ALS (n=44) 3.35 ± .19 0.40 ± 0.02 
mDC (n=9) 3.99 ± .48 0.49 ± 0.06 
HC (n=35) 3.98 ± .25 0.54 ± 0.03 
Significance of Model Main Effects (p-values) 
Diagnosis 0.103 0.001* 
Gender 0.475 0.911 
Age at Draw 0.826 0.423 
Pairwise Comparisons by Diagnosis (p-values) 
ALS vs. mDC 0.212 0.129 
ALS vs. HC 0.056 0.001* 
mDC vs. HC 0.986 0.458 
 
*indicates statistical significance at p<0.05. 
 
 I next compared three ALS subgroups to the disease mimic group.  Familial ALS 
patients, limb-onset ALS patients (ALS-L), and ALS patients greater than one year from 
symptom onset both exhibited reduced levels of cystatin C in the CSF when compared to 
disease mimics (Table 10), with improved p-values when compared to the analysis including all 
ALS patients.  However, the pair-wise comparisons between these ALS subgroups and mimic 
disease controls still fell short of statistical significance.   
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Table 10.  Summary of CSF subgroup results for total and percent cystatin C.  The diagnostic 
potential of cystatin C levels for differentiating ALS patients from mimic DC was higher for three 
ALS subgroups, FALS, ALS-L, and ALS>1yr, than for all ALS patients combined.  ALS = all ALS 
patients; FALS = familial ALS; ALS-L = limb-onset ALS; ALS>1yr = patients with first biofluid 
draw occurring more than one year following symptom onset.   
 N 
Mean Total 
Cystatin C 
(ug/ml) ± 
S.E.M. 
Significance 
of Pairwise 
Difference (p-
values) 
Mean Percent 
Cystatin C  ± 
S.E.M. 
Significance 
of Pairwise 
Difference (p-
values) 
ALS vs 
mimic DC 
44/9 
3.35 ± 0.19 vs 
3.99 ± 0.48 
0.212 
0.40 ± 0.02 vs 
0.49 ± 0.06 
0.129 
FALS vs 
mimic DC 
8/9 
3.06 ± 0.39 vs 
3.99 ± 0.48 
0.127 
0.36 ± 0.04 vs 
0.49 ± 0.06 
0.065 
ALS-L vs 
mimic DC 
35/9 
3.33 ± .021 vs 
4.00 ± 0.49 
0.196 
0.40 ± 0.02 vs 
0.49 ± 0.06 
0.098 
ALS>1yr vs 
mimic DC 
29/9 
3.24 ± 0.22 vs 
3.99 ± 0.48 
0.151 
0.39 ± 0.03 vs 
0.49 ± 0.06 
0.093 
 
 
 Finally, I calculated the diagnostic sensitivity and specificity for several cutoff 
concentration values of CSF cystatin C.  Total cystatin C concentration measurements were 
found to have better diagnostic parameters than percent cystatin C values.  A cutoff value of 
2.20 µg/ml identified a small subset of ALS patients (sensitivity: 23%) with relatively high 
specificity (88% vs. all study controls, 100% vs. mimic disease controls).  A cutoff value of 2.70 
µg/ml identified a modest subset of ALS patients (sensitivity: 32%) while maintaining high 
specificity versus controls (specificity: 78% vs. all study controls, 100% vs. mimic disease 
controls).  A less conservative cutoff value of 3.50 µg/ml identified a majority of ALS patients 
(sensitivity: 52%), but demonstrated lower specificity (specificity: 52% vs. all study controls, 89% 
vs. mimic disease controls). 
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 As noted above, cystatin C was previously reported to be significantly reduced in the 
CSF of ALS patients using mass spectrometry-based proteomics, but the between-group 
differences based on the ELISA data were less robust.  To explore the relationship between 
CSF cystatin C levels measured by these two techniques, I compared the ELISA results with 
SELDI-TOF-MS data for the same CSF samples.  I found significant, positive correlations 
between the 13.3 kDa SELDI-TOF-MS mass peak intensity for cystatin C and both total cystatin 
C and percent cystatin C protein levels as measured by ELISA (p=0.002 and p<0.001, 
respectively; Figure 3).  However, the correlation coefficients (Spearman r=0.443 and 0.595, 
respectively) suggest that these techniques may be differentially sensitive to various modified 
forms of native cystatin C.  
 
 
 
Figure 3.  Correlation of ELISA-based cystatin C levels and SELDI-TOF-MS 13.3 kDa mass 
peak intensity levels.  The relationship between first-draw CSF cystatin C levels evaluated in the 
same samples by ELISA and SELDI-TOF-MS was assessed by Spearman correlation analysis 
(GraphPad Prism 5.0).  Both total (A) and percent (B) cystatin C ELISA measurements directly 
correlated to the 13.3 kDa mass peak intensity for cystatin C (p=0.002 and p<0.001, 
respectively), with Spearman correlation coefficients of r=0.443 and r=0.595, respectively. 
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 I repeated the group analysis for the diagnostic utility of cystatin C in plasma, and both 
measures of cystatin C varied significantly by diagnosis and age, but not by gender (Table 11). 
Post-hoc analyses revealed that total and percent cystatin C were significantly increased in both 
ALS patients and disease controls relative to healthy controls. However, there were no 
differences in cystatin C levels between ALS patients and disease controls.  Identical trends 
were observed for all subgroup analyses of cystatin C levels in plasma (Table 12).  
 
Table 11.  Plasma main group results for total and percent cystatin C.  Both measures of 
cystatin C differed significantly by age at draw and by diagnostic category.  Cystatin C levels 
were significantly elevated in ALS patients and disease controls relative to healthy controls but 
there were no differences in cystatin C levels between ALS patients and disease controls.  ALS 
= all ALS patients; DC = neurological disease controls; HC = healthy controls. 
 Total Cystatin C Percent Cystatin C 
 Mean (ug/ml) ± S.E.M. Mean (%) ± S.E.M. 
ALS (n=43) 0.818 ± 0.024 1.06 × 10-3 ± 3.36 × 10-5 
DC (n=11) 0.861 ± 0.048 1.12 × 10-3 ± 6.78 × 10-5 
HC (n=31) 0.705 ± 0.023 0.89 × 10-3 ± 3.17 × 10-5 
Significance of Model Main Effects (p-values) 
Diagnosis 0.001* <0.001* 
Gender 0.457 0.293 
Age at Draw 0.004* 0.003* 
Pairwise Comparisons by Diagnosis (p-values) 
ALS vs. DC 0.442 0.419 
ALS vs. HC 0.001* <0.001* 
DC vs. HC 0.004* 0.002* 
 
*indicates statistical significance at p<0.05. 
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Table 12.  Plasma subgroup results for total and percent cystatin C.  Both measures of cystatin 
C differed significantly by age at draw and by diagnostic category.  Cystatin C levels were 
significantly elevated in ALS patients and disease controls relative to healthy controls but there 
were no differences in cystatin C levels between ALS patients and disease controls.  ALS = all 
ALS patients; FALS = familial ALS; HC = healthy controls; mDC = mimic disease controls; SALS 
= sporadic ALS. 
 Total Cystatin C Percent Cystatin C 
ALS vs. mDC vs. HC 
   Mean (ug/ml) ± S.E.M. Mean (%) ± S.E.M. 
ALS (n=43) 0.820 ± 0.024 1.06 × 10-3 ± 3.37 × 10-5 
mDC (n=7) 0.843 ± 0.060 1.09 × 10-3 ± 8.42 × 10-5 
HC (n=31) 0.707 ± 0.024 0.89 × 10-3 ± 3.22 × 10-5 
Significance of Model Main Effects (p-values) 
Diagnosis 0.004* 0.001* 
Gender 0.432 0.407 
Age at Draw 0.002* 0.002* 
Pairwise Comparisons by Diagnosis (p-values) 
ALS vs. mDC 0.715 0.738 
ALS vs. HC 0.001* <0.001* 
mDC vs. HC 0.039* 0.026* 
SALS/FALS vs. mDC vs. HC Total Cystatin C Percent Cystatin C 
 
Mean (ug/ml) ± S.E.M. Mean (%) ± S.E.M. 
SALS (n=36) 0.813 ± 0.026 1.05 × 10-3 ± 3.59 × 10-5 
FALS (n=7) 0.851 ± 0.059 1.13 × 10-3 ± 8.48 × 10-5 
mDC (n=7) 0.843 ± 0.060 1.09 × 10-3 ± 8.37 × 10-5 
HC (n=31) 0.707 ± 0.024 0.89 × 10-3 ± 3.20 × 10-5 
Significance of Model Main Effects (p-values) 
Diagnosis 0.009* 0.002* 
Gender 0.435 0.419 
Age at Draw 0.002* 0.002* 
Pairwise Comparisons by Diagnosis (p-values) 
SALS/FALS vs. mDC 0.648 / 0.917 0.627 / 0.721 
SALS/FALS vs. HC 0.003* / 0.026* 0.001* / 0.008* 
mDC vs. HC 0.039* 0.026* 
 
*indicates statistical significance at p<0.05. 
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 To further characterize the relationship between CSF and plasma cystatin C levels, I 
assessed the correlation between CSF and plasma cystatin C levels for individual subjects.  The 
results indicated that there is no correlation between total cystatin C concentrations (Spearman 
r=0.055; p=0.626) or percent cystatin C levels (Spearman r=-0.076; p=0.501) in CSF and 
plasma samples drawn from individual patients on the same day (Figure 4).  The absence of a 
relationship between CSF and plasma cystatin C levels suggests that this protein is 
independently regulated in both biofluid pools, and that plasma cystatin C is unlikely to be 
directly influenced by CSF levels.  
 
 
 
Figure 4.  Correlation analysis for cystatin C levels in CSF and plasma.  The relationship 
between ELISA-based cystatin C measurements in CSF and plasma samples drawn from 
individual patients on the same day was assessed by Spearman correlation analysis (GraphPad 
Prism 5.0).  There was no correlation between total cystatin C concentrations (A) (r=0.055; 
p=0.626) or percent cystatin C levels (B) (r=-0.076; p=0.501).   
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2.4.4 Cystatin C as a Biomarker for Disease Progression 
I next examined whether cystatin C levels change over time in ALS patients, and if these 
changes are associated with clinical disease progression.    I compiled the first CSF draws for 
each of the ALS patients in this study and carried out linear regressions comparing both total 
and percent cystatin C with the time from symptom onset.  Similar to a prior study [139], I found 
no statistically significant linear relationship between these variables in my data set (Figure 5).  
However, I did observe a slight trend toward a reduction in cystatin C levels over time from 
symptom onset, particularly for percent cystatin C (Figure 5B).   
 
 
 
Figure 5.  Linear regressions for CSF cystatin C levels vs. time from symptom onset.  The slope 
of the best-fit lines (solid) for both total (A) and percent (B) cystatin C did not significantly differ 
from zero (p=0.368 and p=0.193, respectively).  Dashed line = 95% confidence interval for best-
fit line. 
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Next, I used longitudinal CSF samples from ALS patients to assess the effect of time on 
cystatin C levels using a statistical model for repeated measures.  This experimental design 
controls for individual differences in baseline cystatin C levels, but not for individual differences 
in rate of disease progression.  I collected at least three longitudinal CSF draws from 15 ALS 
patients over a 1-2 year time period for each patient.  When all 15 values were averaged for 
each time point, I did not observe a significant change in cystatin C levels over time (Table 13, 
“All Patients”).     
 To control for individual differences in disease progression speed, I separated ALS 
patients into two groups: fast progressors, who demonstrated a rapid clinical decline during the 
study period, and slow progressors, whose clinical decline was slower than average (see 
methods section).  When the rate of disease progression was included as a factor in the 
statistical model, I found a significant interaction between the effects of time and progression 
speed for total cystatin C measurements (Table 13, Time*Progression Speed column), 
indicating that longitudinal changes in cystatin C concentration follow different patterns in the 
two patient subpopulations.  In order to determine the direction and significance level of the 
longitudinal subgroup changes responsible for this interaction, I applied the repeated measures 
test individually to each patient subgroup.  Mean cystatin C levels in fast progressors decreased 
slightly over time, but this trend did not approach statistical significance.  In contrast, slow 
progressors exhibited a trend of increasing cystatin C levels over time (p=0.058, Table 13), 
which likely accounts for the majority of the time/progression speed interaction.  Similar trends 
were observed for percent cystatin C measurements.  For comparison, I also assessed the 
longitudinal change in CSF cystatin C levels in 9 healthy controls, each with two CSF samples 
drawn 7.5-25.7 months apart (median: 22.6 months).  A repeated measures t-test revealed a 
modest increase in total cystatin C concentration over time in these healthy controls but no 
longitudinal change in percent cystatin C levels (Table 14).   
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Table 13.  Repeated measures tests for the change in total cystatin C concentration over time.  
There were no significant longitudinal changes in CSF cystatin C concentration in ALS patients 
as a combined group, but fast progressors showed a moderate longitudinal decrease and slow 
progressors showed a moderate longitudinal increase.  There was a significant interaction 
between the change in cystatin C concentration over time and patient progression speed (fast 
versus slow progressors) as listed in Time*Progression speed column (p = 0.032).   
Total 
Cystatin C 
(µg/ml) 
Draw 1 
Mean ± 
S.E.M. 
Draw 2 
Mean ± 
S.E.M. 
Draw 3 
Mean ± 
S.E.M. 
Trend 
Over 
Time 
Change 
Over 
Time (p-
values) 
Time*Progression 
Speed (p-value) 
All Patients 
(n=15) 
3.54 ± 
0.27 
3.64 ± 
0.28 
3.62 ± 
0.29 
flat 0.663 N/A 
Fast 
Progressors 
(n=6) 
4.11 ± 
0.30 
4.02 ± 
0.34 
3.82 ± 
0.36 
↓ 0.333 
0.032* 
Slow 
Progressors 
(n=9) 
3.17 ± 
0.20 
3.39 ± 
0.23 
3.49 ± 
0.26 
↑↑ 0.058 
 
*indicates statistical significance at p<0.05. 
 
 
Table 14.  Longitudinal change in CSF cystatin C in healthy controls. 
  
First Draw 
Mean (ug/ml) 
± S.E.M. 
Second Draw 
Mean (ug/ml) 
± S.E.M. 
Mean 
Difference 
(ug/ml) ± 
S.E.M. 
Significance 
of 
Longitudinal 
Change        
(p-value) 
Total Cystatin C 3.09 ± 0.34 3.29 ± 0.34 0.20 ± 0.07 0.028* 
Percent Cystatin C 0.476 ± 0.060 0.478 ± 0.056 0.002 ± 0.008 0.802 
 
*indicates statistical significance at p<0.05. 
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 To determine if CSF Cystatin C can be used as a surrogate marker of ALS progression, I 
evaluated the correlation between changes in Cystatin C levels and time-matched changes in 
clinical disease progression.  For all patients with longitudinal CSF samples, I compared the 
change in Cystatin C between the first and last available time points with the change in three 
clinical measures of ALS disease progression over the same time period.  For this analysis, I 
assessed both the absolute changes in total and percent Cystatin C as well as the percent 
change in each of these measures (normalized by the first draw value in order to control for 
individual differences in baseline levels).  No significant correlations were found between any of 
the four measures of Cystatin C and any of the three clinical measures of disease progression 
(Table 15).  These results indicate that longitudinal changes in Cystatin C do not correlate with 
time-matched changes in these clinical measures of disease progression and, therefore, they do 
not support the utility of this protein as a surrogate biomarker for ALS. 
 
Table 15.  Correlation analysis for Cystatin C levels vs. time-matched clinical measures of 
disease progression.  No significant correlations were found.  The p-values given are two-tailed, 
and are not adjusted for multiple comparisons.  ALS-FRS-R = ALS revised functional rating 
scale; MM = manual muscle strength; FVC = forced vital capacity; Spearman ρ = nonparametric 
correlation coefficient.   
  
 
Δ Cystatin C 
concentration 
Δ Percent 
Cystatin C 
normalized Δ 
Cystatin C 
concentration 
normalized 
Δ Percent 
Cystatin C 
Δ ALSFRS 
(n=20) 
Spearman r 0.019 0.126 0.053 0.109 
p-value 0.937 0.596 0.824 0.646 
Δ FVC 
(n=13) 
Spearman r -0.526 -0.259 -0.425 -0.270 
p-value 0.065 0.394 0.148 0.373 
Δ MMT 
(n=20) 
Spearman r 0.219 0.285 0.250 0.212 
p-value 0.353 0.223 0.287 0.370 
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2.4.5 Correlation of Cystatin C to Survival 
Finally, I assessed the relationship between first-draw cystatin C levels (in CSF and plasma) 
and patient survival time.  Neither measure of plasma cystatin C showed a correlation with 
subsequent survival time (total cystatin C: Spearman r=-0.17, p=0.537), but both measures of 
CSF cystatin C levels showed a direct correlation, with the results for total cystatin C almost 
reaching statistical significance (total cystatin C: Spearman r=0.465, p=0.052).  These findings 
suggest that cystatin C levels in CSF but not plasma may be useful as prognostic indicators of 
patient survival time.   
 I further explored this correlation by generating Kaplan-Meier survival curves for total 
CSF cystatin C measurements.  For these analyses, patients were sorted into high- and low-
cystatin C groups according to their first-draw cystatin C levels.  Qualitative data assessment 
revealed that short survival times were most strongly associated with the lowest cystatin C 
levels and, for this reason, I selected a cut-off value of 2.75 µg/ml to separate the ALS patients 
into a smaller low cystatin C group (n=11) and a larger high cystatin C group (n=21).  This 
analysis revealed significantly longer patient survival in the high cystatin C group than in the low 
cystatin C group (Figure 6A).  Next, because the ALS disease course and average survival time 
differ significantly between limb-onset ALS and bulbar-onset ALS, I repeated these statistical 
tests with exclusively limb-onset patients.  Within this population, the between-group difference 
in post-draw survival time became even more striking (Figure 6B), further reinforcing my finding 
that ALS patients with low CSF cystatin C levels exhibit reduced survival times relative to 
patients with average to high CSF cystatin C levels.  Similar results were obtained using percent 
cystatin C measurements.   
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Figure 6.  Kaplan-Meier survival curves.  For all ALS patients (A), survival was significantly 
longer (p<0.014) in patients with high cystatin C levels (top curve, n=21) than in patients with 
low cystatin C levels (bottom curve, n=11).  For patients with limb onset ALS (B), the same 
trend was observed, but with a larger survival difference (p<0.010) between patients with high 
(top curve, n=13) and low (bottom curve, n=10) cystatin C levels.   
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2.5 DISCUSSION 
The present study represents a comprehensive evaluation of cystatin C as a candidate 
biomarker in ALS, and is unique in its assessment of two distinct biofluids (CSF and blood 
plasma), two different measurements of the protein of interest (total concentration and percent 
of total protein), and longitudinally collected CSF samples.    
2.5.1 Biofluid Total Protein Levels 
I measured the total protein concentration in all CSF and plasma samples in order to normalize 
cystatin C concentrations to total biofluid protein levels for further biomarker assessment.  In 
agreement with the literature [161], I found protein concentrations to be increased in the CSF, 
but not the plasma, of ALS patients relative to healthy controls.  Interestingly, CSF total protein 
concentrations in neurological disease controls were also increased relative to healthy controls, 
but did not differ from the protein levels observed in ALS patients.  This indicates that elevated 
CSF protein is a common finding in neurological disease and is not specific to ALS.  
2.5.2 Diagnostic Utility of Cystatin C 
Prior studies using SELDI-TOF-MS found significantly lower cystatin C abundance in the CSF of 
ALS patients relative to healthy controls [137] and mixed healthy/neurological disease controls 
[136].  These findings were validated by ELISA and immunoblot, respectively.  In this larger 
ELISA evaluation of diagnostic utility, I also found a significant reduction in cystatin C levels in 
the CSF of ALS patients relative to healthy controls, but the magnitude of this difference was 
less robust than in the previous reports.  This discrepancy may have resulted from the use of 
different experimental techniques, as SELDI-TOF-MS recognizes discrete mass-to-charge 
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forms of cystatin C, whereas ELISA may recognize multiple modified or cleaved forms of 
cystatin C.  Regarding the comparison of these two techniques, I found a significant, positive 
correlation but a low correlation coefficient between the CSF ELISA data and SELDI-TOF-MS 
data for the same samples (Figure 3).  This finding suggests that these techniques are sensitive 
to different, but possibly overlapping, ranges of native cystatin C forms, and may provide 
differential, and perhaps complementary, utility in detecting cystatin C for biomarker 
assessment.  Notably, a very recent study used a third assay, a latex turbidimetric 
immunoassay, to compare CSF cystatin C in ALS patients and healthy controls, and reported no 
difference between these experimental groups [134]. 
To be clinically useful as a diagnostic biomarker, cystatin C must be able to differentiate 
between ALS patients and individuals with neurological diseases that closely resemble ALS, or 
ALS “mimic diseases.”  A recent study reported a significant reduction in CSF cystatin C levels 
in ALS patients relative to polyneuropathy patients [139].  In my ELISA analysis, cystatin C was 
reduced in the CSF of ALS patients relative to all DC combined (Table 8) and, to a greater 
degree, relative to a mimic disease control group that included a variety of ALS mimics (Table 
9), but neither difference reached statistical significance.  Because these between-group 
differences were smaller than I expected based on previous mass spectrometry data [138], I 
conducted a new power analysis using my experimentally-derived group means and standard 
deviations.  This analysis revealed that this study was adequately powered for comparing 
percent cystatin C between ALS and HC (a significant difference was found), and underpowered 
for comparing the smaller effect sizes observed for total cystatin C between ALS and HC (main 
group effects missed significance, but the pairwise comparison was significant), and for 
comparing ALS with DC for both measures of cystatin C (no significant differences were 
identified).  The observed reductions in both total and percent cystatin C in ALS patients relative 
to DC may reflect actual differences in clinical cystatin C levels, but a total study enrollment of 
1020 and 675 patients (for total and percent cystatin C, respectively) would be required to 
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confirm statistical significance with 80% power and 95% confidence.  Interestingly, the between-
group differences and trend towards significance improved when comparing limb-onset ALS 
patients or ALS patients with disease course greater than 1 year from symptom onset to the 
ALS mimics (Table 10).  Additionally, by comparing data using total cystatin C concentration 
versus percent cystatin C, I found that the total concentration measurement generated superior 
diagnostic accuracy, indicating that this may be the more efficacious measure of cystatin C.  An 
assessment of the diagnostic parameters of CSF cystatin C concentration revealed that the 
sensitivity of cystatin C for differentiating ALS patients from disease controls is relatively low for 
all cutoff values with clinically acceptable levels of specificity and, therefore, cystatin C can only 
identify a small subset of ALS patients.  Together, these findings indicate that CSF cystatin C 
levels may differ between ALS patients and relevant disease control populations but cystatin C, 
by itself, has limited diagnostic utility.  However, this protein could potentially improve the 
sensitivity and/or specificity of a diagnostic biomarker panel.  Due to the heterogeneous nature 
of the ALS patient population, it is likely that a multiple biomarker panel will be required, as 
opposed to any single protein biomarker, in order to differentiate ALS from related disorders 
with adequate diagnostic certainty [37]. 
I also assessed the diagnostic utility of plasma cystatin C levels.  Plasma cystatin C has 
been extensively characterized as a peripheral biomarker for kidney function and as a 
prognostic indicator of the risk of morbidity and mortality relating to cardiovascular disease [104, 
183].  However, blood-borne levels of cystatin C have not been evaluated as a biomarker 
candidate for neurological disorders.  I found that plasma cystatin C levels are equivalently 
elevated in both ALS patients and disease controls relative to healthy controls, indicating that 
elevated plasma cystatin C is a nonspecific finding associated with neurological disease states.  
Therefore, plasma cystatin C levels, as evaluated by ELISA, do not to have diagnostic utility for 
ALS.  Furthermore, the absence of a relationship between cystatin C levels in concurrently-
drawn CSF and plasma samples from individual patients in this study (Figure 4) suggests that 
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this protein is independently regulated in each biofluid.  Accordingly, plasma cystatin C levels 
are unlikely to be directly correlated with motor neuron degeneration in ALS, though elevated 
levels may correlate to peripheral metabolic or inflammatory abnormalities during ALS.   
The statistical model I used to complete these analyses included subject age and sex as 
a covariate and a factor, respectively.  This allowed the model to control for between-group 
differences in these variables (the data were not age- and sex-matched) in the case that 
cystatin C concentrations are statistically related to either variable.  It also allowed us to 
statistically test the main effects of both variables on cystatin C concentration.  Cystatin C 
concentration in plasma has previously been reported to be slightly higher in men than in 
women, and to increase significantly with age [184].  To my knowledge, an assessment of these 
relationships in CSF has not been previously published.  In this analysis, plasma cystatin C 
concentration and percent cystatin C were both found to vary significantly with age, but no 
relationship with sex was observed.  In contrast, no relationship was observed between either 
measure of CSF cystatin C and either demographic variable.  It is possible that this study was 
underpowered to detect small potential relationships between CSF cystatin C and patient 
age/sex.  However, it is more likely that the relationships observed in plasma cystatin C levels, 
which depend mainly on renal clearance of the protein [104], are not present in CSF due to 
different mechanisms of protein regulation.   
2.5.3 Surrogate Utility of Cystatin C 
A recent study examined a single CSF draw per ALS patient, taken at varying times from 
symptom onset, to indirectly infer the average longitudinal change in cystatin C concentration in 
the group as a whole, and they reported that cystatin C levels do not change over time [139].  I 
completed a similar analysis and also found no evidence for a patterned directional change in 
CSF cystatin C levels over time in ALS patients (Figure 5).  However, both heterogeneity in 
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disease progression speed and individual variation in baseline cystatin C levels could mask 
significant trends in cystatin C change over the course of disease progression and, therefore, 
single-draw protein levels are unsuitable for a thorough assessment of longitudinal trends in 
cystatin C abundance.   
I also examined longitudinal CSF data from multiple patients to more accurately assess 
the changes in cystatin C over time.  I found that longitudinal cystatin C concentrations were 
relatively constant in ALS patients as a combined group.  In contrast, the subgroup of patients 
with slow or absent clinical disease progression exhibited longitudinal increases in cystatin C 
concentration, and the subgroup with more typical, continuous clinical deterioration exhibited 
longitudinal decreases in total cystatin C.  Interestingly, slow progressors often exhibited lower 
initial levels of CSF cystatin C than fast progressors (Table 13).  Similar trends were also 
observed for percent cystatin C measurements, but statistical significance was not reached.  
These results indicate that CSF cystatin C levels in ALS patients change over time in a 
clinically-relevant manner and that increasing cystatin C concentration may be associated with 
slower disease progression.  Conversely, rapid disease progression may be associated with a 
decrease in cystatin C concentration over time.  
I also conducted an analysis to determine the relationship between longitudinal changes 
in CSF cystatin C levels and time-matched changes in three functional clinical measures of 
disease progression (ALSFRS-R, MMT, and FVC).  However, no significant correlations were 
found.  It is possible that this correlation does exist in fast progressors, but the inclusion of slow 
progressors obscured the relationship.  Unfortunately there were inadequate numbers of fast 
progressors to assess these correlations individually.    
The absence of a correlation with clinical measures indicates that cystatin C levels may 
change independently of the clinical parameters used for monitoring disease progression.  
However, this finding does not eliminate the possibility that changes in CSF cystatin C levels 
correlate with more subtle biochemical changes in pathophysiological disease progression, as 
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these may not be accurately reflected by overt functional measures of clinical disease status 
[175, 176].  Furthermore, the observed trend of increasing cystatin C levels in patients with slow 
rates of clinical deterioration may prove to be useful as an objective biomarker for monitoring 
drug effects in clinical trials.   However, a larger validation study is needed to confirm the 
existence of this trend. 
2.5.4 Prognostic Utility of Cystatin C 
 We recently demonstrated a correlation between CSF cystatin C levels and patient survival by 
SELDI-TOF-MS [138].  In this study, I further verified a direct correlation between CSF cystatin 
C concentration and patient survival time, supporting the potential utility of this protein for 
prognostic applications.  Subsequent Kaplan-Meier survival analyses for patient groups with 
CSF cystatin C concentrations above and below qualitatively selected cut-off values confirmed 
significantly longer survival times for patients in the higher cystatin C groups.  Additionally, the 
prognostic capacity of CSF cystatin C was higher for limb-onset patients (Figure 6B) than for all 
patients combined (Figure 6A).  This may have resulted from the confounding effects of 
combining patients with different sites of disease onset, as bulbar-onset ALS patients typically 
have shorter survival times than limb-onset patients [172, 173].  Unfortunately, there were 
inadequate numbers of bulbar-, trunk-, and/or dementia-onset patients to analyze these 
individual subgroups in this study, and further analyses are required to determine the prognostic 
capacity of cystatin C in these subgroups.  Nonetheless, these results show that cystatin C is a 
candidate prognostic indicator of survival in ALS patients.  Alternatively, cystatin C levels could 
contribute to the process of balancing prognostic variables among experimental groups as 
recommended to equalize drop-out rates and preserve the balancing effects of randomization in 
clinical trials [175].  Further work is required to more fully characterize the relationship between 
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CSF cystatin C concentration and ALS patient survival, and to determine optimal cut-off values 
and procedures to stratify patients for prognostic purposes. 
2.5.5 Implications for Disease Pathogenesis  
The results of this comprehensive biomarker assessment also have implications for the potential 
mechanistic involvement of cystatin C in the pathogenesis of ALS.  The function of cystatin C 
within the CNS has not been extensively studied, but it appears to have both neurotoxic and 
neuroprotective properties [127, 144, 145, 148], though its effects specifically on motor neurons 
have not been reported.  The majority of cystatin C in the CSF is produced by the choroid 
plexus [121], but it is unclear whether the apparent reductions in CSF levels in ALS patients are 
an independent etiological factor contributing to motor neuron degeneration, a downstream 
result of disease pathogenesis, or a compensatory response to ALS pathology.  However, the 
association of higher cystatin C concentrations with longer patient survival and the association 
of increasing cystatin C levels with slower clinical progression both suggest that extracellular 
cystatin C may exhibit neuroprotective properties within the context of ALS.   This would 
implicate any absolute or relative cystatin C deficiency in ALS as both a potential contributor to 
disease pathogenesis and a potential therapeutic target.  Continuing work in our laboratory is 
focused on determining the effects of altered cystatin C concentration/activity on motor neurons 
in vitro, in order to clarify its potential mechanistic role in ALS pathogenesis. 
2.5.6 Summary and Conclusions 
In summary, I have completed a comprehensive evaluation of cystatin C as a candidate ALS 
biomarker, including assessments of two complementary measures of cystatin C in two distinct 
biofluids as well as examinations of both longitudinal CSF samples and patient survival data.  
 68 
My findings indicate that cystatin C levels, as determined by ELISA, are increased in the plasma 
and decreased in the CSF of ALS patients relative to normal controls.  CSF cystatin C 
measurements may possess a more limited diagnostic capacity for ALS than previously 
proposed, but may still have the potential to improve the diagnostic parameters of a biomarker 
panel.  Additionally, longitudinal changes in CSF cystatin C levels may be useful as a biomarker 
of fast versus slow rates of disease progression.  My data also demonstrated that CSF cystatin 
C concentration has prognostic utility in estimating patient survival time.  Further validation 
studies are necessary to confirm these findings and ultimately determine if cystatin C 
measurements can be used to enhance clinical disease management and clinical trial design.  
Finally, the association of high or increasing cystatin C levels with slower disease progression 
and increased survival time suggests a potential neuroprotective role for this protein in the 
pathobiology of ALS.  Further studies are necessary to test this hypothesis. 
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3.0  CYSTATIN C ACTIVITY IN ALS 
3.1 ABSTRACT  
Cystatin C is a constitutively expressed cysteine protease inhibitor that appears to be 
differentially abundant in the CSF of ALS patients relative to healthy controls.  The function of 
cystatin C within the CNS is not well understood, but it has been shown to exhibit both 
neurotoxic and neuroprotective properties, suggesting that altered cystatin C concentration 
could potentially impact ALS pathogenesis.  Recent findings suggest numerous potential 
neuroprotective roles for this protein in some neurodegenerative disorders, but additional 
characterization in ALS is required.  Because the neuroactive effects of cystatin C are most 
likely due to its activity as a cysteine protease inhibitor, it is important to first determine whether 
changes in Cystatin C concentration are accompanied by proportional changes in its total 
activity within the context of human disease.  To this end, a papain inhibition assay was used to 
evaluate the total CSF cystatin C activity in 23 ALS patients, 23 healthy controls, and 23 
neurological disease controls.  Total cystatin C concentration was also measured by ELISA.  In 
all subjects, the total cystatin C activity was confirmed to be directly related to its concentration.  
Additionally, there were no differences in the mean activity ratio (total activity / total 
concentration) of cystatin C among the three diagnostic groups.  This indicates that it is unlikely 
that cystatin C is differentially modified in these subject groups in any way that affects protein 
activity. Therefore, total CSF cystatin C activity can be inferred from total concentration data.  
These findings will allow further interpretation of CSF cystatin C concentration levels that have 
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been reported at multiple time points during the disease course.  Additionally, they provide new 
evidence for a protective role of cystatin C during ALS development and progression.  
3.2 INTRODUCTION 
High-throughput screening techniques such as mass spectrometry have enabled the recent 
identification of multiple biofluid proteins with differential abundance in ALS patients relative to 
controls.  These proteins may be useful as disease-specific biomarkers and may also provide 
insight regarding disease pathogenesis.  The differential concentration of these proteins could 
reflect a contributing factor in disease pathogenesis or protective responses.  This would reveal 
a direct, pathogenic or protective role for the implicated proteins.  Alternatively, differentially 
abundant proteins could represent downstream products of disease-related events, and could 
implicate specific biological pathways in the disease processes.  Therefore, functional 
evaluations of putative protein biomarkers within the context of human disease have the 
potential to provide valuable information regarding ALS pathogenesis. 
 One recently identified protein with potential for biomarker utility and pathogenic 
correlates is the constitutively expressed cysteine protease inhibitor cystatin C.  This protein 
appears to be less abundant in the CSF of ALS patients relative to healthy controls, as 
measured by both mass spectrometry [136-138] and ELISA (section 2.4.3).  Because cystatin C 
is also known to exhibit variable neuroactive properties, this alteration in CNS abundance could 
potentially play a role in ALS pathogenesis through the reduction of a neuroprotective or 
neurotoxic function.   
 Cystatin C is also an attractive candidate for a role in disease pathogenesis due to its 
apparent alterations in CNS expression and intracellular localization.  In postmortem spinal cord 
tissue from ALS patients, cytoplasmic immunostaining is markedly decreased in both motor 
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neurons and astrocytes relative to controls.  In ALS motor neurons, intense cystatin C staining is 
generally limited to occasional proteinaceous intracytoplasmic inclusions known as Bunina 
bodies, which are relatively specific to ALS.  Additionally, cystatin C expression information 
drawn from publically available microarray data sets (generated using motor cortex and spinal 
cord tissue from humans and transgenic mice) suggests a possible decrease in protein 
expression in early motor neuron disease [185, 186] and a possible increase in protein 
expression during later phases of disease [185-189].  Finally, one direct study of cystatin C 
regulation in transgenic ALS mice identified both a slight increase in cystatin C expression, and 
an increase in cytoplasmic cystatin C aggregation within motor neurons [143].   
 These observations support a pattern of cystatin C dysregulation throughout multiple 
CNS compartments.  Intracellular changes in cystatin C expression and processing may affect 
neural survival on their own and may contribute to extracellular differences, as cystatin C is 
processed primarily through the secretory pathway.  However, this study will focus on the 
contributions of extracellular cystatin C to disease pathogenesis.   
 The neuroactive effects of Cystatin C in the CSF and extracellular fluid likely result 
primarily from its activity as a cysteine protease inhibitor [145], specifically its action against the 
papain-like and calpain-like cysteine proteases.  These proteases interact with cystatin C at a 
common active site and comprise the vast majority of its known targets [103].  These effects are 
less likely to stem from the inhibition of legumain-like cysteine proteases, which have a primarily 
lysosomal distribution, interact with cystatin C at a distinct active site, and are thought to play a 
role in antigen presentation [107].  Cystatin C activity against extracellular cathepsins and 
calpains may protect against proteolytic tissue damage and neuronal death following CNS injury 
[109, 190].  Additionally, both types of proteases appear to be upregulated in ALS, suggesting 
an elevated need for regulatory protease inhibition [191, 192].   
 Cystatin C has also been proposed to mediate neuroprotection independently of 
protease inhibition through the induction of macroautophagy [193], the regulation of cell 
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proliferation [194, 195], and the inhibition of amyloid-beta oligomerization [109, 196-198].  
However, the latter two activities are unlikely to relate to ALS pathophysiology, and the potential 
roles in autophagy have not been verified in vivo or in motor neurons [109].  Although the 
dysregulation of autophagy has been reported in ALS, it remains unclear whether the induction 
of autophagy is a detrimental or productive process [199]. 
 The most likely pathways for the involvement of extracellular cystatin C in ALS 
pathogenesis are contingent upon its activity as an inhibitor of papain-like and calpain-like 
cysteine proteases.  Therefore, before drawing conclusions regarding the likely contributions of 
reduced CSF cystatin C to ALS pathogenesis, it is necessary to first confirm that these 
concentration differences are mirrored by proportional differences in CSF cystatin C activity.  If 
there are no differences in CSF cystatin C activity ratio (total activity / total concentration) 
between ALS patients and controls, then mean cystatin C concentrations can be used to 
estimate relative cystatin C activity levels among experimental groups, and conclusions can be 
drawn regarding the potential roles of altered CSF cystatin C concentration in ALS 
pathogenesis. 
 The purpose of this study was to evaluate the relationship between cystatin C 
concentration and activity in the CSF of ALS patients and controls.  A papain-inhibition assay 
was used to measure total cystatin C activity against its primary targets, and a quantitative 
ELISA was used to measure total cystatin C concentration.  I hypothesized that the activity of 
cystatin C would be directly proportional to its concentration, and that the ratio of cystatin C 
activity to concentration would be equivalent in all experimental groups.   
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3.3 MATERIALS AND METHODS 
3.3.1 Sample Selection 
For this study on the functional activity of cystatin C, 69 first-draw CSF samples were selected 
from the set collected for biomarker assessment (section 2.3.1).  All nine mimic disease controls 
(listed in section 2.3.1) were included, and then the selector was blinded to both sample number 
and cystatin C concentration.  An additional 23 ALS samples, 23 HC samples, and 14 DC 
samples were then selected to balance the three experimental groups by age and sex (Table 
16).  In addition to the mimic disease controls, the DC group included four patients with multiple 
sclerosis, one with bilateral facial palsies, one with neurosarcoidosis, one with viral encephalitis, 
one with CNS lymphoma, one with brain metastases, one with pseudotumor cerebri, one with a 
seizure disorder, one with complicated migraine, one with paresthesis and possible myelopathy, 
and one with a probable conversion disorder. 
 
Table 16.  Demographic characteristics of study participants.  There were no significant 
differences between subject age or gender among groups.  
  ALS (n=44) 
Healthy 
Controls 
(n=35) 
Disease 
Controls 
(n=25) 
Sex 
(male/female) 
11/12 11/12 12/11 
Age at  draw ± 
SD (years) 
48.7 ± 13.9 48.7 ± 14.2 48.5 ± 15.4 
Relevant 
subgroups 
18 sporadic, 5 
familial 
NA 
9 ALS mimics, 
6 MS, 10 other 
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3.3.2 Immunoprecipitation 
Immunoprecipitation (IP) of cystatin C from CSF samples was performed using a magnetic bead 
system (MACS Molecular, Auburn, CA).  First, 7.5 μL of affinity-purified goat anti-human cystatin 
C polyclonal antibody (R&D Systems, Minneapolis, MN) were added to each 15 μL CSF sample 
and the solutions were briefly mixed at room temperature.  Next, 52 μL of Protein A MicroBeads  
were added to each sample, and the solutions were mixed and incubated for 30 min on ice.  
During this incubation, the μ columns (MACS Molecular, Auburn, CA) were each primed with 
200 μL of lysis buffer (50mM Tris HCl, pH=6.00; 150mM NaCl; 1% Triton-X-100), and then 
rinsed with 100 μL of assay buffer (see papain inhibition assay below).  Also, triethylamine 
elution buffer (pH 11.8, 0.1% Triton X-100) and 1X SDS gel loading buffer were warmed to 95 
°C on a heating block.  Next, the CSF solutions were applied to the μ columns and the "flow-
through" solutions were collected.  An additional 30 μL of assay buffer were then added to flush 
the remaining CSF solutions into the flow-through collection tube.  The columns were each 
rinsed with 50 μL of PBS and the flow-through solutions from this rinse were saved again.  The 
columns were then rinsed with an additional 750 μL of PBS and 100 μL of low-salt wash buffer 
(50mM Tris HCl, pH 6.8; 50mM DTT; 1% SDS; 0.005% bromophenol blue; 10% glycerol).  To 
elute the isolated cystatin C, 20 μL of pre-heated 1X SDS gel loading buffer were added to each 
μ column and incubated for 5 min at room temperature.  Next, an additional 50 μL of pre-heated 
1X SDS gel loading buffer were added to each column and the flow-through was collected.   
3.3.3 Immunoblotting 
IP elution products were diluted 3:4 in Tricine Sample Buffer (Bio-Rad Laboratories, Hercules, 
CA) and separated by electrophoresis on a NuPAGE® Novex® 12% Bis-Tris polyacrylamide gel 
(Invitrogen, Carlsbad, CA), with 20µl of elution solution per lane.  The proteins were transferred 
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onto a PolyScreen polyvinylidene difluoride membrane (NEN Biolabs, Ipswich, MA) and blocked 
with 5% nonfat milk in 1X TBS/0.05% Tween-20 (TBST) for one hour at room temperature.  A 
mouse monoclonal anti-human cystatin C primary antibody (Santa Cruz Biotechnology, Santa 
Cruz, CA) was added to the blocking solution at a 1:1000 dilution and incubated overnight at 
4°C.  The membrane was thoroughly washed with 1X TBST, and then a goat anti-mouse 
horseradish peroxidase-conjugated secondary antibody (Millipore, Burlington, MA) was diluted 
by 1:5000 in 5% nonfat milk in 1X TBST and applied to the membrane for two hours at room 
temperature.  The membrane was thoroughly washed with 1X TBST, and then the labeled 
proteins were visualized using Chemiluminescence Reagent Plus (PerkinElmer, Waltham, MA). 
3.3.4 Papain Inhibition Assay 
3.3.4.1 Assay Design 
Sample were randomized to plates and plate positions, and assayed in triplicate wells.  Each 
sample and its corresponding sample/antibody solution were always assayed in adjacent wells.  
A standard curve (in duplicate) and an internal standard of mixed CSF (in triplicate) were also 
included on each plate for quality control.  The experiment was repeated with samples in 
reverse order on each plate to control for slight assay differences based on plate position.  
3.3.4.2 Assay Procedure 
The procedure I developed for this study was modified from an R&D Systems activity assay 
protocol for Recombinant Human Cystatin C protein (R&D Systems, Minneapolis, MN).  Plant-
derived papain (Sigma, St. Louis, MO) was diluted to 100 µg/mL in ice-cold activation buffer (50 
mM Tris, 5 mM DTT, pH 7) and incubated at room temperature for 15 min.  CSF samples from 
each patient were then diluted 2:3 in either assay buffer (50 mM Tris, pH 7) or cystatin C 
blocking antibody (R&D Systems, Minneapolis, MN; diluted in assay buffer) and incubated with 
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gentle agitation for five min at room temperature.  The CSF sample solutions were then further 
diluted by 1:8 in assay buffer, and the activated papain solution was further diluted to 2 ug/mL in 
assay buffer.  Equal volumes of the CSF and papain solutions were mixed and then incubated 
at 37 ºC for 10 min.  The incubated mixture was then diluted 1:5 in assay buffer, and 50 µL were 
added to each well of a black 96-well plate.  Next, 50 µL of the Z-Phe-Arg-AMC (R&D Systems, 
Minneapolis, MN) substrate solution (10 mM in DMSO, diluted to 200 µM in assay buffer) were 
rapidly added to each well using a multi-channel pipetter, and the plate was immediately 
inserted into a plate reader.  The plate was read for 5 min in kinetic mode, using excitation and 
emission wavelengths of 380 nm and 460 nm, respectively. 
3.3.5 Statistical Analysis 
All statistics were carried out using SPSS software.  Data normality was assessed by the 
Kolmogorov-Smirnova and Shapiro-Wilk tests, and normality was only assumed when indicated 
by both tests.  All calculated p-values were two-tailed, and the significance level was set at 
p<0.05. 
3.3.5.1 Papain Inhibition Assay Data Processing 
For each experiment, the reaction rate for each well was determined as slope of best-fit line of 
graphed RFU data.  Intra-assay CVs were then calculated using the three reaction rates for 
each sample (and each sample/antibody mixture) on each plate.  Data from one of the triplicate 
well readings was dropped from all analyses when it differed from both other wells by a CV ≥ 
40, and the two similar wells differed from each other by a CV less than half of the average CV 
between the outlier and the similar wells.  The reaction rates for the remaining wells for each 
sample were then averaged.  The average reaction rate for each raw CSF sample (without 
blocking antibody) was recorded as the total assay activity for that sample.  The total assay 
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activity was then subtracted from the average reaction rate for the same sample with blocking 
antibody to determine the total cystatin C activity for that sample.   
 Inter-assay CVs were determined for each sample using the total assay activity and, 
separately, the total cystatin C activity calculated for each run.  For samples that were assayed 
more than twice, plate data for assay activity and cystatin C activity were both dropped when 
one of the two measurements on a plate that differed from the other plate data by the same CV 
rule applied for triplicate well readings.  The remaining plate data were averaged to determine 
the final assay activity and cystatin C activity for each sample. 
3.3.5.2 Assessment of Papain Inhibition Assay Performance 
Coefficients of variation between duplicate/triplicate wells for each sample run and between 
mean plate results for each sample were recalculated after dropping outlier data.  The individual 
CVs for all sample-runs were averaged to determine the overall intra-assay CV.  Similarly, the 
cystatin C activity CVs for all samples were averaged to determine the overall inter-assay CV.  
Because both groups of CV data failed normality (intra-assay CV: p<0.001 for both normality 
tests; inter-assay CV: Shapiro-Wilk p=0.003), the median values were also calculated and 
reported. 
3.3.5.3 Correlation Analyses 
The correlations between cystatin C concentration and both assay activity and cystatin C activity 
in all samples as a combined group were assessed using non-parametric statistics because the 
data for total assay activity data were non-normally distributed (Shapiro-Wilk p=0.028).  For 
these analyses, SPSS software was used to calculate both the Spearman correlation coefficient 
and the two-tailed significance level.  Identical methods were used to assess the same 
correlations in each diagnostic group because cystatin C concentrations in ALS patients also 
failed normality testing (Shapiro-Wilk p=0.039). 
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3.3.5.4 Comparison of Original Diagnostic Groups 
Because cystatin C activity ratios were normally distributed in all three experimental groups and 
there were no significant differences among group variances, we compared group means by 
one-way ANOVA.   
 For our final comparison of cystatin C concentration, total assay activity, and total 
cystatin C activity between groups, all diagnostic group data were normally distributed except 
for cystatin C concentration (Shapiro-Wilk p=0.039).  For each data category, differences 
among diagnostic group means were identified by one-way ANOVA.  Differences among 
diagnostic group medians for cystatin C concentration were also determined using Kruskal-
Wallis one-way ANOVA.   
3.3.5.5 Analysis of Samples Paired by Cystatin C Concentration 
Samples in all three diagnostic groups were paired by cystatin C concentration, and the seven 
samples in each group which could not be paired with samples from the other groups were 
dropped from this analysis.  All paired data for cystatin C concentration, total assay activity, total 
cystatin C activity, and cystatin C activity ratio were normally distributed.  Therefore, we were 
able to use the SPSS general linear model for repeated measures to assess differences in each 
of the four variables among diagnostic groups.   
3.4 RESULTS 
3.4.1 Principle of the Assay 
This assay determines the total cysteine protease inhibitor (CPI) activity in a fluid sample by 
measuring its ability to inhibit papain, a plant-derived cysteine protease.  Papain hydrolyzes the 
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Arg-AMC amide bond of the Z-F-R-AMC substrate and releases the highly fluorescent 7-amino-
4-methyl coumarin (AMC) group.  Relative fluorescence units (RFU) are then measured with a 
plate reader to determine the total papain activity.  When a CPI is added to the assay solution, it 
inhibits papain-mediated Z-F-R-AMC substrate cleavage, and fluorescence emission is reduced.  
The total activity of the CPI can then be estimated as the reduction in papain-mediated assay 
activity.   
 There are several challenges when using this assay to measure the activity of a specific 
CPI within a biofluid sample, such as CSF.  First, because CSF contains several CPIs, the total 
assay inhibition is a measure of the combined CPI activity and cannot be attributed to a single 
protein.  Additionally, CSF also contains endogenous cysteine proteases that could potentially 
cleave the Z-F-R-AMC substrate and supplement papain activity.  This would increase the 
overall fluorescence emission and decrease the apparent CPI activity determined by the assay.   
 I controlled for these factors and determined the total cystatin C activity in CSF by 
assaying both raw CSF and CSF from the same patient sample that was pre-incubated with an 
antibody that blocks cystatin C activity.  For the raw CSF, the total measured assay activity 
included the supplementary effects of all endogenous cysteine proteases as well as the 
inhibitory effects of all CPIs present in the sample.  For the CSF/blocking antibody solution, the 
measured assay activity included all of the factors present in raw CSF except for the inhibitory 
activity of cystatin C.  Therefore, the total activity of cystatin C of each sample could be 
calculated by subtracting the total assay activity for raw CSF from the total assay activity for 
CSF/blocking antibody solution. 
3.4.2 Effectiveness of Blocking Antibody 
Preliminary experiments were conducted to test the effectiveness of the cystatin C blocking 
antibody in eliminating cystatin C activity from CSF samples.  The CSF sample from this study 
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with the highest cystatin C concentration was used for all preliminary tests.  First, an IP protocol 
was developed to efficiently remove cystatin C from CSF, using the polyclonal blocking antibody 
as the IP capture antibody.  As expected, cystatin C activity was eliminated from the "flow-
through" sample solutions because the protein was retained within the IP column (Figure 7).  
Next, CSF samples were pre-incubated with the same polyclonal blocking antibody and then 
assayed according to the standard protocol.  Samples demonstrated an antibody-dose-
dependent elimination of inhibitory activity (Table 17), with full inhibition achieved by a sample to 
antibody ratio of 2:1 (Table 17; 2:1 case only shown in Figure 7).  These findings confirm that 
this polyclonal antibody effectively eliminates all cystatin C activity from raw CSF samples. 
 
Table 17.  Dose-dependent effect of cystatin C activity-blocking antibody.  The CSF sample with 
the highest cystatin C concentration was pre-incubated with varying amounts of polyclonal 
cystatin C activity-blocking antibody and then tested in the papain inhibition assay.  Case 1 
demonstrates the baseline assay activity in the absence of CSF-mediated inhibition, and Case 2 
demonstrates the full magnitude of assay inhibition produced by the selected CSF sample.  
Addition of the of the blocking antibody in Cases 3-6 demonstrates a dose-dependent 
elimination of CSF-mediated assay inhibition, with full inhibition reached at a 4:2 ratio (assay 
activity returns to baseline). 
Case CSF to Antibody Ratio 
Mean Assay Activity 
(RFU/sec) 
1 0:4 3114 
2 4:0 628 
3 4:1 2045 
4 4:2 3286 
5 4:3 3166 
6 4:4 3002 
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Papain Inhibition Assay 
 
Western Blot 
Case Experimental Condition 
Mean Assay 
Activity 
(RFU/sec) 
 
  
 A IP buffers without CSF 5663 
    B IP: CSF 98 
    C IP: CSF + capture/blocking antibody 5566 
    D Assay buffers without CSF 3782 13 kDa → 
   E CSF 997 
    F CSF + capture/blocking antibody 4152 
 
1 2 3 
 
Figure 7.  Capture/blocking antibody eliminates CSF cystatin C activity as effectively as cystatin 
C removal by IP.  CSF samples were exposed to various treatments and then tested in the 
papain inhibition assay.  All final CSF dilutions were equivalent.  IP elution products were 
examined by immunoblotting, and a human cystatin C positive control is shown in column 1.  
For cases A-C, samples were passed through an IP column and the flow-through solution 
assayed.  The use of IP buffers did not eliminate baseline assay activity (case A).  When 
capture/blocking antibody was omitted, cystatin C remained in the flow-through and no protein 
was isolated by the IP (column 2).   Additionally, samples retained their inhibitory activity and 
the assay activity was reduced (case B).  When capture/blocking antibody was included, 
cystatin C was removed from the flow-through solution, and was eluted from the IP column by 
additional steps (column 3).  Additionally, inhibitory activity of the flow-through sample was lost, 
and assay activity returned to baseline (case C).  For cases D-F, the standard protocol was 
used and samples were not passed through IP columns.  Baseline assay activity was lower 
using standard protocol buffers (case D), compared to IP buffers (case A).  Under standard 
assay conditions, without the addition of capture/blocking antibody, inhibitory activity of the 
sample substantially reduced assay activity (case E).  Addition of the capture/blocking antibody 
eliminated inhibitory activity of the sample, and assay activity returned to baseline (case F).   
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3.4.3 Papain Inhibition Assay Performance 
Intra-assay CVs were determined for all triplicate wells testing CSF samples and CSF + 
blocking antibody solutions.  The CVs were non-normally distributed (range: 0.1-29.9), and the 
median was within the preferable range for intra-assay variability (Table 18).  Because mean 
CVs are more commonly reported in the literature, the mean CV was also determined (Table 
18), and also fell within the acceptable range. 
 Inter-assay CVs were determined using the final cystatin C activity level determined in 
each replicate run of each sample.  The CVs were non-normally distributed (range: 0.2-32.1), 
and both the median and the mean were well within the preferable range for inter-assay 
variability (Table 18).   
 
Table 18.  Papain inhibition assay variability. 
  Median Mean 
Intra-assay CV 3.6 5.2 
Inter-assay CV 9.1 10.2 
 
3.4.4 Relationship Between CSF Cystatin C Concentration and Activity 
Before separating the data into diagnostic groups, we graphed both total assay activity and total 
cystatin C activity as functions of cystatin C concentration.  We observed a strong, indirect 
relationship between CSF cystatin C concentration and total assay activity (Figure 8), and a 
strong, direct relationship between cystatin C concentration and its own activity.   
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Figure 8.  Correlation of cystatin C concentration with papain inhibition assay activity and 
cystatin C activity.  Total assay activity was indirectly related to cystatin C concentration (A), and 
the relationship was statistically significant (p<0.001, Spearman r = -0.861).  Total cystatin C 
activity was directly related to its own concentration (B), and the correlation was strong and 
significant (p<0.001, Spearman r = 0.883). 
 
 Next, the data were sorted into diagnostic categories and the correlation analyses were 
repeated.  The relationships observed in the combined data were both maintained in all three 
diagnostic categories, and all correlations were statistically significant (Table 19).   
 
Table 19.  Nonparametric correlations in each diagnostic group. 
    Total Assay Activity 
Total Cystatin C 
Activity 
ALS (n=23) 
Spearman r -0.915 0.857 
p-value <0.001* <0.001* 
HC (n=23) 
Spearman r -0.852 0.824 
p-value <0.001* <0.001* 
DC (n=23) 
Spearman r -0.808 0.871 
p-value <0.001* <0.001* 
 
*indicates statistical significance at p<0.05. 
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3.4.5 Comparison of Cystatin C Activity Ratios Among Diagnostic Groups 
Next, cystatin C activity ratios were calculated for all samples by dividing the total cystatin C 
activity by the total cystatin C concentration.  The mean activity ratios were compared across 
groups using one-way ANOVA, and there were no differences between any experimental 
groups (Table 20).   
 
Table 20.  Mean activity ratios for each diagnostic group.  There was no significant difference 
between group means.  
  N Mean ± SD One-way ANOVA 
ALS 23 739 ± 109 
p=0.312 HC 23 702 ± 115 
DC 23 691 ± 111 
 
 To confirm these results and control for differences in mean cystatin C concentration 
among groups, we paired data by cystatin C concentration and compared activity ratios (as well 
as the other three data categories) using statistics for repeated measures.   Again, no significant 
differences were observed among the three experimental groups (Table 21).  
 
Table 21.  Repeated measures assessment of cystatin C activity.  When samples were paired 
by cystatin C concentration, there were no significant differences in assay activity, cystatin C 
activity, or cystatin C activity ratio among the three diagnostic groups.  
 
N 
Mean Cystatin C 
Concentration ± 
SD 
Mean Assay 
Activity ± SD 
Mean Cystatin C 
Activity ± SD 
Mean Activity 
Ratio ± SD 
ALS 16 3.54 ± 1.03 1151 ± 665 2505 ± 543 729 ± 110 
HC 16 3.53 ± 1.03 1194 ± 652 2508 ± 576 729 ± 101 
DC 16 3.54 ± 1.05 1230 ± 841 2449 ± 689 702 ± 124 
p-value 0.859 0.796 0.843 0.597 
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3.4.6 Comparison of Mean Cystatin C Activity Among Diagnostic Groups 
Finally, we compared mean cystatin C total activity among the three original diagnostic groups, 
which were not balanced by cystatin C concentration.  For comparison, we also assessed 
differences in total assay activity and cystatin C concentration among the three groups.  
Cystatin C concentration was analyzed with both parametric and non-parametric statistics 
because the assumption of normality was narrowly missed in the ALS patient data.  In this 
analysis, the trends in mean cystatin C activity mirrored the between-group trends in mean 
cystatin C concentration, but neither difference reached statistical significance (Table 22).  The 
trends in mean assay activity were inversely related to the trends in mean cystatin C 
concentration, but also fell short of statistical significance (Table 22). 
 
Table 22.  Comparison of cystatin C concentration, assay activity, and cystatin C activity among 
experimental groups.  No differences among experimental groups reached statistical 
significance.  Group medians were compared by Kruskal-Wallis one-way ANOVA, and group 
means were compared by one-way ANOVA. 
 
N 
Median Cystatin 
C Concentration 
Mean Cystatin C 
Concentration ± 
SD 
Mean Assay 
Activity ± SD 
Mean Cystatin C 
Activity ± SD 
ALS 23 2.72 3.09 ± 1.10 1453 ± 766 2219 ± 635 
HC 23 3.90 3.84 ± 1.13 1085 ± 618 2603 ± 528 
DC 23 3.27 3.51 ± 1.07 1289 ± 817 2390 ± 708 
p-value 0.081 0.077 0.247 0.124 
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3.5 DISCUSSION 
To my knowledge, this study represents the first direct measurement of cystatin C activity within 
the CSF.  To accomplish this aim, I developed a papain inhibition assay, which utilized an anti-
cystatin C blocking antibody to enable the specific assessment of cystatin C within raw CSF 
samples.  This assay was performed with extremely low inter-assay and intra-assay variability, 
and allowed the reliable evaluation of cystatin C activity in multiple CSF samples from ASL 
patients and controls.  Notably, this assay measures only the activity of cystatin C at its primary 
active site, which interacts with papain-like and, presumably, calpain-like cysteine proteases.  
Therefore, the experimental findings of this study will only apply to the activity of cystatin C 
against its primary ligands, and will not address its interactions with legumain-like cysteine 
proteases. 
 As expected, cystatin C concentration demonstrated a strong, direct relationship with the 
magnitude of its inhibitory activity.  This confirms that CSF cystatin C is biologically active 
against papain-like cysteine proteases, and there does not appear to be significant variability in 
the activity state of the protein among individual subjects.  However, the average activity per 
protein unit does appear to be somewhat concentration dependent, as the slope of the best-fit 
line is less than one (i.e. doubling cystatin C concentration does not fully double total activity).   
 Cystatin C concentration also demonstrated a strong, indirect relationship with the 
overall activity of the papain assay.  This indicates that the raw CSF samples tested in this 
assay induce an overall inhibitory effect on papain-mediated protease activity, and this effect is 
almost entirely dependent upon cystatin C concentration.  The correlation coefficients for both of 
these relationships were nearly identical, indicating that the contributions of endogenous 
papain-like cysteine proteases and alternate cysteine protease inhibitors to assay activity were 
all extremely minimal.  Therefore, cystatin C appears to be the dominant cysteine protease 
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inhibitor in the CSF, and to maintain an environment with a net inhibitory effect on cathepsin-
mediated proteolysis.  
 When the data were divided into diagnostic groups, comparable correlations were 
maintained between cystatin C concentration and both its own activity and total papain assay 
activity in each group.  This finding is in agreement with the low apparent variability in cystatin C 
activity state among individuals in the combined group.  Activity ratios were then calculated for 
each patient as the total cystatin C activity divided by the total cystatin C concentration, and the 
resulting mean values did not statistically differ among the three experimental groups.  This 
verifies the hypothesis of this study and indicates that relative cystatin C activity differences can 
be directly inferred from relative concentration differences among these experimental groups.  
However, it must be noted that slight, non-significant differences in group activity ratios were 
observed, and were consistent with an inverse concentration dependence of cystatin C activity 
(i.e. average activity ratios decrease slightly with increasing average cystatin C concentration).  
This pattern of concentration dependence indicates that differences in mean activity between 
groups are likely to be smaller than corresponding differences in mean concentration. 
 In order to control for the proposed concentration dependence of CSF cystatin C activity, 
I next paired patient data from the three diagnostic groups according to cystatin C 
concentration.  I then evaluated differences in all four data categories among diagnostic groups 
using repeated measures statistics.  There were no notable or statistical differences among 
groups for any of the evaluated variables, indicating that data pairing was successful (no 
difference in cystatin C concentration) and that, in the absence of concentration-dependent 
effects, there is no difference in the average activity per protein unit among patient populations 
(no difference in activity ratio).  This indicates that the kinetics of CSF cystatin C activity are 
constant across these three experimental groups.  Accordingly, it is unlikely that there are 
differential activity-changing protein modifications or agents present in the CSF among these 
three patient populations.   
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 To apply these findings to between-group differences in our age- and sex-matched data 
set, I next assessed the differences in mean/median cystatin C concentration, mean cystatin C 
activity, and mean assay activity among the three diagnostic groups.  Unfortunately, although 
the relative trends in cystatin C concentration were in agreement with previously reported 
differences (ALS<DC<HC; Section 2.4.3), they fell just short of statistical significance.  The 
earlier findings of this study (concentration-dependent cystatin C activity with equivalent kinetics 
across groups) would predict a directly proportional trend in total cystatin C activity 
(ALS<DC<HC) and an inversely proportional trend in total assay activity (ALS>DC>HC), both 
with a smaller effect size.  In fact, this is exactly what was observed, and the smaller effect size 
is reflected by the higher p-values for the latter two comparisons.  These findings support the 
previous conclusions, but indicate that this study was probably underpowered to detect 
differences in overall cystatin C concentration and activity between experimental groups, due to 
the high inter-patient variability in these measures.  However, the study was adequately 
powered to compare activity ratios, as the inter-patient variability for this measure was 
significantly lower.  Therefore, the previous conclusions can be maintained with confidence. 
 These findings indicate that published findings regarding CSF cystatin C concentration in 
ALS patients and normal controls can be interpreted to infer proportional differences in cystatin 
C activity between these patient populations.  Changes relative to disease controls may also be 
proportional, but this assumption should be made consciously, as disease controls vary by 
study and some disorders not included in the present work may exhibit changes in the kinetics 
of cystatin C activity.    
 Most studies that have examined cystatin C abundance in the CSF of ALS patients have 
reported reduced levels relative to both healthy controls and disease controls [136-139].  
Considering that cystatin C is the predominant active CPI in the CSF, it follows that there is a 
state of reduced CPI activity in the CSF of ALS patients.  This change may be relatively without 
consequence, or it may contribute to either toxic or protective pathways relating to ALS 
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pathogenesis.  Cystatin C has been reported to exhibit neurotoxic effects when injected into the 
rodent brain [144], and when directly applied to primary neuronal cultures [145].  However, 
cystatin C also exhibits neuroprotective effects both in vivo [127] and in vitro [148], and potential 
neuroprotective pathways of cystatin C have been more thoroughly characterized [109].  The 
protective function that appears most relevant to ALS, is the regulation of extracellular 
cathepsins and calpains that are released as part of physiological processes or in response to 
CNS damage or stress.  The levels of these proteases may be elevated in ALS due to increased 
expression [191, 192], secretion by activated microglia [200], and/or release by dying neurons 
[191, 201-204].  Therefore, the reduced CSF cystatin C activity in ALS may be inadequate to 
counteract the apparent increase in protease activity, resulting in protease-mediated CNS 
damage. 
 Extracellular cystatin C also may be internalized by motor neurons and/or glial cells, and 
subsequently effect intracellular processes.  Efficient cystatin C uptake has been demonstrated 
in vitro, in multiple non-neuronal human cell lines [205].  If this process also occurs in the human 
CNS, reduced extracellular cystatin C concentration could result in reduced uptake and 
abnormal deficiencies in intracellular cystatin C activity.  Intracellular cathepsins and calpains 
both appear to be upregulated in ALS, and can both contribute to the induction of apoptosis 
[191, 192].  Therefore, deficiencies in intracellular cystatin C could potentially lead to apoptosis 
through the loss of a protective mechanism. 
 In summary, this study demonstrated the CSF cystatin C activity is directly proportional 
to its concentration in ALS patients and controls.  Accordingly, reported reductions in CSF 
cystatin C abundance can be inferred to indicate that total CPI activity is also reduced in the 
CSF of ALS patients.  This may implicate cystatin C as an active participant in ALS 
pathogenesis, as this protein demonstrates both neurotoxic and neuroprotective properties 
within the CNS.   Additional work will be required to clarify the impact of diminished extracellular 
cystatin C with respect to general functions within the CSF and direct effects on motor neurons.   
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4.0  CSF FREE HEMOGLOBIN AS AN INDICATOR OF BLOOD-CNS BARRIER 
DISRUPTION IN ALS 
4.1 ABSTRACT 
Recent studies have suggested that endothelial cell damage and blood-CNS barrier (BCNSB) 
breakdown occur in transgenic rodent models of the motor neuron disease amyotrophic lateral 
sclerosis (ALS).  This disruption of the BCNSB may release toxic, blood-derived substances into 
the brain or spinal cord of these transgenic rodents, facilitating or inducing motor neuron 
degeneration.  To determine if blood-derived proteins accumulate in the cerebrospinal fluid 
(CSF) of ALS patients, CSF free hemoglobin levels were quantified by ELISA in 274 ALS 
patients, 121 neurological disease controls, and 84 healthy controls.  In this study, elevated 
CSF free hemoglobin was found to be significantly more prevalent in ALS patients than in 
patients with other neurological disorders and healthy individuals.  This result suggests that 
BCNSB damage occurs in some sporadic and familial ALS patients during the symptomatic 
phase of the disease.  The observed elevations in free hemoglobin may also contribute to 
disease pathogenesis, as both hemoglobin and hemoglobin-derived substances can be toxic to 
motor neurons. 
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4.2 INTRODUCTION 
Functional breakdown of the blood-brain barrier (BBB) and the blood spinal cord barrier (BSCB) 
occurs in a variety of neurodegenerative diseases, and can act as either a primary initiating 
event or as a secondary contributing factor in disease pathogenesis [155].  These barriers, in 
addition to the blood-CSF barrier (BCSFB), can be collectively referred to as the blood-CNS 
barrier (BCNSB).  The presence of free hemoglobin in the CSF can be an indicator of BCNSB 
damage because it is a byproduct of red blood cell (RBC) breakdown, and RBC’s are 
completely excluded from the CSF by these barriers in non-pathologic states.  Alternatively, free 
hemoglobin in CSF can be an artifact of a traumatic spinal tap, which can result in the 
accumulation of blood into the collected CSF.  Hemoglobin is also one of many blood-derived 
proteins with the potential to contribute to CNS damage following BCNSB compromise, as it is 
toxic to spinal neurons in vitro via an iron-dependent, oxidative mechanism [170]. 
Amyotrophic lateral sclerosis (ALS) is a fatal neurological disease characterized by rapid 
and progressive degeneration of motor neurons in the brain and spinal cord.  The majority of 
cases arise sporadically, but a familial link is observed in approximately ten percent of cases.  
Disease pathogenesis is poorly understood and, although disruption of all three blood-CNS 
barriers is thought to occur [159, 160], its mechanistic relationship to disease development and 
progression is unknown.  The occurrence of BCNSB breakdown in ALS patients is suggested by 
elevations in the CSF albumin/serum albumin ratio observed in some ALS patients [161-163], 
as well as post-mortem evidence of endothelial cell activation and/or injury in the spinal cord in 
some patients [164, 165].  The timing of these phenomena with regard to disease progression is 
unclear in humans, but has been examined in rodent models of familial ALS.  Ultrastructural and 
functional examinations of BBB and BSCB integrity in rodents expressing mutant human 
superoxide dismutase 1 (SOD1) have shown endothelial cell damage and vascular leakage in 
areas of motor neuron degeneration at both early and late stages of disease [153, 167-169].  
 92 
Furthermore, vascular microhemorrhages and leakage of neurotoxic, hemoglobin-derived 
products have been reported to occur at close proximity to motor neurons before motor neuron 
degeneration [167] and at presymptomatic stages of disease [168].  These findings suggest that 
BBB and BSCB damage may play a primary pathogenic role in transgenic rodents over 
expressing mutant SOD1 protein.  However, the leakage of toxic substances through the BBB 
and BSCB has not previously been reported in ALS patients [206], and further work is needed to 
confirm BBB/BSCB disruption in human disease and to clarify its relationship to disease 
pathogenesis.  The results presented here provide further evidence for the existence of BCNSB 
breakdown in a subset sporadic and familial ALS patients during the symptomatic phase of the 
disease, and suggest a potential mechanism through which this damage could contribute to 
disease progression. 
4.3 MATERIALS AND METHODS 
4.3.1 Sample Collection 
This study was approved by the institutional review boards at the University of Pittsburgh and 
Massachusetts General Hospital, and informed consent was obtained from all participating 
subjects.  CSF was collected from 274 symptomatic ALS patients, 84 healthy controls (HC), and 
121 neurological disease controls (DC) at two clinical sites, the University of Pittsburgh Medical 
Center and Massachusetts General Hospital (Table 23), using identical collection procedures.  
ALS subjects were diagnosed by neurologists specialized in motor neuron disease, using 
revised El Escorial criteria [19], and included 241 patients with sporadic ALS and 33 patients 
with familial ALS.  HC research subjects lacked any neurological symptoms, and DC subjects 
included 43 patients with Alzheimer’s disease, 27 with multiple sclerosis, 15 with peripheral 
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neuropathy, 8 with lower motor neuron disease, 7 with upper motor neuron disease, 2 with 
frontotemporal dementia, 2 with chronic inflammatory demyelinating polyneuropathy (CIDP), 2 
with spinocerebellar ataxia, 2 with myelopathy, 1 with bilateral facial palsies, 1 with 
neurosarcoidosis, 1 with viral encephalitis, 1 with CNS lymphoma, 1 with brain metastases, 1 
with pseudotumor cerebri, 1 with a seizure disorder, 1 with complicated migraine, 1 with 
paresthesis and possible myelopathy, 1 with a probable conversion disorder, 1 with progressive 
muscular atrophy, 1 with small fiber neuropathy, and 1 with idiopathic sensorimotor 
polyneuropathy.  CSF was obtained by a lumbar puncture that was carried out for research 
purposes only, and none of the samples exhibited visible blood contamination.  All samples 
were immediately centrifuged at 450 g for five minutes at 4°C to remove cells and debris, 
aliquoted, and then frozen at -80°C. 
 
Table 23.  Demographic characteristics of CSF samples.  N/A = not applicable. 
 ALS HC DC 
Total 274 84 121 
Age (Mean ± SD) 54 +/- 14 47 +/- 16 55 +/- 16 
Sex (M/F) 191 / 83 38 / 47 57 / 64 
Disease Type (Sporadic/Familial) 241 / 33 N/A N/A 
 
4.3.2 ELISA 
The CSF samples were thawed on ice immediately prior to use, and free hemoglobin levels 
were measured using a Human Hemoglobin ELISA Quantitation Set, according to the 
manufacturer's instructions (Bethyl Laboratories, Montgomery, TX).  Briefly, 100 ul of coating 
antibody (diluted 1:100 in ELISA Coating Buffer) were added to each well of a 96-well plate and 
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incubated overnight at 4°C.  The plate was washed with TBST and then 200 ul of BlockerTM 
Casein (Pierce Biotechnology, Rockford, IL), diluted in TBS, were added to each well for 30 min 
at room temperature.  The plate was washed again and 100 ul of CSF (diluted 1:10 in BlockerTM 
Casein in TBS) were added to each well for one hour at room temperature.  The plate was 
washed and 100 ul of HRP Detection Antibody (diluted 1:40,000 in BlockerTM Casein in TBS) 
were added to each well for one hour at room temperature.  After washing the plate a final time, 
100 ul of TMB Substrate Solution were added to each well and allowed to develop in the dark 
for 15 minutes at room temperature.  The reaction was stopped by adding 100 ul of 1N HCl to 
each well, and then absorbance was measured at 450 nm using a plate reader.  All samples 
were measured in duplicate, and final free hemoglobin concentrations were calculated using a 
standard curve generated by the absorbance of serially diluted Human Hemoglobin Calibrator 
standards. 
4.3.3 Statistical Analysis 
Because CFS samples were collected and assayed at two clinical sites, I first compared free 
hemoglobin distributions between clinical sites for each experimental group, to confirm that the 
assay results were comparable at each site and the data could be combined.  The data in all six 
groups were strongly right-skewed, and the distributions from both sites were roughly 
equivalent.  For all remaining analyses, the data from both clinical sites were combined. 
 Differences among the three experimental group medians were identified by Kruskal–
Wallis one-way analysis of variance.  Pairwise differences between group medians were then 
assessed using two-tailed Mann–Whitney–Wilcoxon tests.   
 Next, free hemoglobin levels were classified into three groups (high, medium, and low), 
and two-tailed Chi Square tests were used to compare the free hemoglobin level distribution 
patterns among and between experimental groups.   
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 Finally, data from the two control groups were combined, and I conducted a receiver 
operating characteristic (ROC) analysis to evaluate the diagnostic capacity of CSF free 
hemoglobin concentration for identifying ALS patients from all study controls. 
 All statistical analyses were completed using SPSS software, and p-values less than 
0.05 were considered to be significant. 
4.4 RESULTS 
4.4.1 Nonparametric Assessment of Diagnostic Group Medians 
The median CSF free hemoglobin concentrations were 63, 6, and 41 ng/ml for ALS, DCs, and 
HCs, respectively.  Significant differences in median CSF free hemoglobin concentrations 
among these diagnostic groups were identified by non-parametric statistics (p < 0.001), and 
subsequent, pairwise comparisons revealed significantly increased free hemoglobin levels in 
ALS patients compared to DCs (p < 0.001, Figure 9). 
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Figure 9.  CSF free hemoglobin concentration in ALS patients, HCs and DCs.  Horizontal lines 
represent mean values.  Three ALS patients had CSF free hemoglobin levels that fell above the 
given Y-axis of this scatter plot (17018, 31776, and 23881).  Kruskal–Wallis one-way analysis of 
variance identified a significant difference (p < 0.001) in the median values among the three 
groups.  Post-hoc Mann–Whitney–Wilcoxon tests identified a statistically significant difference 
between the ALS and DC group medians (**p < 0.001), but the difference between the ALS and 
HC group medians fell short of statistical significance (p = 0.107). 
 
4.4.2 Chi Square Tests of Free Hemoglobin Level Distribution 
To assess differences in CSF free hemoglobin distribution, I grouped free hemoglobin levels 
into three categories (low, medium and high) as follows:  Low < 1000 ng/ml (82% of samples); 
Medium = 1000 – 3000 ng/ml (10% of samples); and High > 3000 ng/ml (8% of samples).  The 
1000 ng/ml cutoff was selected as an upper limit of the minimal free hemoglobin contamination 
typically observed in around 82% of CSF samples collected by lumbar tap (insert reference).  
The 3000 ng/ml cutoff was selected to generate a more conservative lower limit for free 
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hemoglobin levels that are potentially attributable to BCNSB disruption, rather than collection-
related blood contamination. 
 An initial Chi Square test identified a significant difference in the distribution of free 
hemoglobin levels among the three experimental groups (Pearson 2-sided p=0.002; Table 24), 
with an increased proportion of medium and high free hemoglobin levels in ALS patients relative 
to both HCs and DCs.  There were inadequate numbers of familial ALS patients to separately 
analyze the distribution of free hemoglobin levels in this subgroup.  However, I did observe an 
increased proportion of high free hemoglobin levels in these patients relative to controls (Low: 
87.9%, Medium: 6.1%, High: 6.1%), which was similar, but less robust, to the trend observed in 
the combined ALS group. 
 
Table 24.  Chi Square analysis of main group differences.  The observed free hemoglobin level 
distribution differed significantly among the three diagnostic groups. 
 
Free Hemoglobin Level 
Low Medium High 
Diagnosis 
ALS 
Observed Count* 209 31 34 
Expected Count 224.2 26.9 22.9 
% within Diagnosis 76.3% 11.3% 12.4% 
DC 
Observed Count* 109 8 4 
Expected Count 99.0 11.9 10.1 
% within Diagnosis 90.1% 6.6% 3.3% 
HC 
Observed Count* 74 8 2 
Expected Count 68.7 8.2 7.0 
% within Diagnosis 88.1% 9.5% 2.4% 
 
* Pearson 2-sided p=0.002. 
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 Post-hoc Chi Square tests were then performed to determine which diagnostic groups 
exhibited pairwise differences in CSF free hemoglobin distribution.  Elevated CSF free 
hemoglobin was found to be significantly more common in ALS patients than both HCs 
(Pearson 2-sided p=0.021; Table 25) and DCs (Pearson 2-sided p=0.004; Table 26), and the 
differences were most prominent at high free hemoglobin levels.  The free hemoglobin 
distributions in the two control groups did not differ (Pearson 2-sided p=0.703; Table 27). 
 
Table 25.  Pairwise comparison of ALS and HCs.  The observed distribution of free hemoglobin 
levels differed significantly between ALS patients and HCs, primarily due to the increased 
prevalence of high free hemoglobin levels in ALS patients. 
 
Free Hemoglobin Level 
Low Medium High 
Diagnosis 
ALS 
Observed Count* 209 31 34 
Expected Count 216.6 29.8 27.6 
% within Diagnosis 76.3% 11.3% 12.4% 
HC 
Observed Count* 74 8 2 
Expected Count 66.4 9.2 8.4 
% within Diagnosis 88.1% 9.5% 2.4% 
 
* Pearson 2-sided p=0.021. 
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Table 26.  Pairwise comparison of ALS and DCs.  The distribution of free hemoglobin levels 
differed significantly between ALS patients and DCs, with higher proportions of ALS patients 
exhibiting both medium and high free hemoglobin levels. 
 
Free Hemoglobin Level 
Low Medium High 
Diagnosis 
ALS 
Observed Count* 209 31 34 
Expected Count 220.6 27.1 26.4 
% within Diagnosis 76.3% 11.3% 12.4% 
DC 
Observed Count* 109 8 4 
Expected Count 97.4 11.9 11.6 
% within Diagnosis 90.1% 6.6% 3.3% 
 
*Pearson 2-sided p=0.004. 
 
Table 27.  Pairwise comparison of HCs and DCs.  The distribution of CSF free hemoglobin 
levels did not differ between these control groups. 
 
Free Hemoglobin Level 
Low Medium High 
Diagnosis 
HC 
Observed Count* 74 8 2 
Expected Count 75.0 6.6 2.5 
% within Diagnosis 88.1% 9.5% 2.4% 
DC 
Observed Count* 109 8 4 
Expected Count 108.0 9.4 3.5 
% within Diagnosis 90.1% 6.6% 3.3% 
 
*Pearson 2-sided p=0.703. 
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4.4.3 ROC Analysis 
Although I am not proposing CSF free hemoglobin concentration as a candidate diagnostic 
biomarker, I next completed an ROC analysis to assess the sensitivity and specificity of CSF 
free hemoglobin levels for differentiating ALS patients from all study control subjects.  In this 
analysis, higher levels of CSF free hemoglobin were significantly associated with an ALS 
diagnosis (p<0.001; Figure 10).  A cutoff value of 3000 ng/ml identified a small subset of ALS 
patients (sensitivity: 12%; specificity: 97%), whereas a cutoff value of 1000 ng/ml identified twice 
as many ALS patients while maintaining relatively high specificity (sensitivity: 24%; specificity: 
89%). 
 
 
Figure 10.  ROC curve for CSF free hemoglobin concentration.  This analysis shows the 
sensitivity and specificity of the full range of observed CSF free hemoglobin values for 
differentiating ALS patients from all study controls.  Higher levels of CSF free hemoglobin were 
associated with an ALS diagnosis, as the area under the ROC curve (0.638) was significantly 
greater than 0.5 (p <0.001). 
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4.5 DISCUSSION 
In this study, I assessed CSF free hemoglobin levels in ALS patients, HCs, and DCs in order to 
make inferences regarding the prevalence of BCNSB dysfunction in these groups. 
 First, I assessed differences in central tendency of free hemoglobin concentrations 
among the three diagnostic groups by using nonparametric statistics to compare group 
medians.  The median CSF free hemoglobin concentration in ALS patients was significantly 
higher than in DCs (p<0.001), but its increase relative to HCs fell short of statistical significance 
(p=0.107).  This result supports the idea that free hemoglobin levels differ between groups, but 
is not ideal for clinical interpretation because all three group medians fall within the "typical" 
range of CSF free hemoglobin collected by lumbar tap.   
 In order to assess the clinically-relevant differences in CSF free hemoglobin level 
distribution among diagnostic groups, I classified free hemoglobin concentrations into three 
groups:  (1) "low" levels, which included free hemoglobin concentrations typically observed in 
CSF collected by spinal tap in subjects without suspected BCNSB compromise, (2) "medium" 
levels, which included free hemoglobin concentrations up to three times higher than the upper 
cut off for the "low" group, and (3) "high" levels, which included free hemoglobin concentrations 
greater than 3,000 ng/ml.  I propose that free hemoglobin levels within the "high" range are 
sufficiently elevated relative to normal levels that it can be inferred that they result from BCNSB 
compromise rather than collection-related blood contamination.  This statistical analyses 
revealed that the distribution of free hemoglobin levels was not equivalent across experimental 
groups (p=0.002) and, specifically, that the distribution for ALS patients differed significantly 
from the distributions for both HCs (p=0.021) and DCs (p=0.004).  This difference was 
accounted for by a large increase in the percentage of ALS patients with high free hemoglobin 
levels, and a small increase in the proportion of ALS patients with medium free hemoglobin 
levels, relative to both control groups.  The large increase in the prevalence of high, as opposed 
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to medium, free hemoglobin levels in ALS patients indicates that the cause of the between-
group differences in free hemoglobin level distribution is likely to result from an in vivo 
pathologic process in ALS patients, rather than any collection-mediated differences. 
 An ROC analysis was also conducted to illustrate the capacity of free hemoglobin 
concentration measurements to differentiate ALS patients from all study controls.  This test 
showed that elevated CSF free hemoglobin is significantly associated with an ALS diagnosis, 
relative to the controls used in this study.  However, the relatively low area under the curve 
(0.638) indicates that CSF free hemoglobin concentration is still a poor measurement to use in 
discriminating ALS from control subjects.  This can also be seen in the "optimal" 
sensitivity/specificity pairs (see results section), which indicate that free hemoglobin 
concentration has extremely limited potential as a diagnostic biomarker.  At best, this 
measurement could potentially improve the diagnostic parameters of a biomarker panel, but 
even in this case a positive result would be nonspecific for neurological disorders with BCNSB 
compromise.  Nonetheless, this analysis statistically examines the data in a third, unique 
manner and provides further evidence that CSF free hemoglobin levels differ significantly 
between ALS patients and controls.  
 Together, these findings indicate that elevated CSF free hemoglobin is significantly more 
common in symptomatic ALS patients than in healthy individuals and patients with some 
neurological diseases.  Notably, there was a higher male-to-female ratio in the ALS group, and 
a lower mean age in the HC group, relative to the other groups.  These differences were unlikely 
to have significantly affected the results because, although normal plasma hemoglobin levels 
are slightly higher in males, hemoglobin is typically undetectable in CSF in non-pathologic 
states, and does not differ by age or sex.  Additionally, while higher levels of physical disability 
in the ALS group may have increased the difficulty of CSF collection, I do not believe that 
collection-related blood contamination differed significantly among groups because all lumbar 
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punctures were performed by experienced neurologists, and any CSF samples with visible 
blood contamination were excluded from the study. 
 Assuming that collection-related blood contamination occurred equally across all subject 
groups, the increased frequency of elevated CSF free hemoglobin in ALS provides insight into 
the disease process.  This finding suggests that the incidence of BCNSB disruption is increased 
in ALS during the symptomatic phase of the disease, and may be either a contributing factor or 
a result of the disease process.  Additionally, because the majority of ALS subjects in this study 
were diagnosed with sporadic ALS, this finding also suggests that research regarding BBB/BSB 
breakdown in animal models of familial ALS may translate to the more prevalent sporadic forms 
of human disease.  This would imply that BBB/BSCB disruption may occur prior to symptom 
onset in both clinical forms of human disease and, if so, is likely to be an integral component of 
disease pathogenesis.  Furthermore, elevated CSF free hemoglobin indicates the release of a 
neurotoxic protein from the blood into the CSF of ALS patients.  Hemoglobin has previously 
been shown to induce dose-dependent degeneration of spinal neurons in vitro via an iron-
dependent, oxidative mechanism [170]. This finding provides additional support for the 
emerging hypothesis that BCNSB disruption contributes to ALS pathogenesis by exposing 
motor neurons to neurotoxic blood-derived substances [160, 167].   
 The etiology of BCNSB disruption in ALS remains uncertain, but some potential 
mechanisms of endothelial cell damage and BCNSB breakdown in this disease are suggested 
by altered levels/regulation of important BCNSB-related proteins in ALS, including VEGF [207, 
208], angiogenin [10, 169], matrix metalloproteinases [209], vasoactive intestinal peptide [208, 
210], and E-selectin [165].  Further research is required to determine whether BBB/BSCB 
disruption occurs prior to motor neuron degeneration in ALS patients, as observed in animal 
models, and whether this process is a primary component of motor neuron disease or a 
secondary result of the disease process.  
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 In summary, these findings contribute to the growing body of evidence supporting the 
existence of BCNSB dysfunction as an integral component of ALS pathogenesis. 
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5.0  DISCUSSION 
This body of work includes evaluations of two potential CSF-based biomarkers for ALS, cystatin 
C and free hemoglobin.  The putative connections of these proteins to ALS pathophysiology 
were discovered independently, and each protein exhibits vastly different biomarker 
characteristics and possible applications.  However, there is a potential physiologic connection 
between these two proteins, and the evaluation of both has led to meaningful conclusions 
regarding ALS pathogenesis. 
5.1 CYSTATIN C AND ALS 
5.1.1 Potential for Biomarker Utility 
My comprehensive evaluation of cystatin C as an ALS biomarker validated some previously 
reported relationships, cast doubt upon others, and added significant new findings to our 
understanding of the regulation and behavior of this protein in ALS.   
5.1.1.1 Diagnostic Utility 
Multiple studies have investigated the diagnostic utility of CSF cystatin C, and most have 
reported significant reductions in cystatin C abundance in ALS patients relative to both healthy 
controls and neurological disease controls [136-139].  My evaluation of these relationships 
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employed more optimal experimental design (larger sample size, more controls for potential 
confounding factors, replication of results, etc.) than several of these prior studies, and my 
results indicated a smaller effect size than all other reports but one [134].  This was particularly 
evident for the difference between ALS patients and neurological disease controls, which did not 
reach statistical significance in my analysis.  However, the cystatin C levels observed in my 
study were significantly lower in ALS patients than in normal controls, indicating that the effect 
size is probably larger relative to this group.  Considering the preponderance of the findings, as 
well as the relative merits and limitations of each study, it appears appropriate to conclude that 
CSF cystatin C does exhibit reduced abundance in ALS patients relative to healthy individuals.  
This conclusion supports a potential role for cystatin C in disease pathogenesis, but does not 
directly reflect diagnostic biomarker utility.  Furthermore, uncertainty remains regarding the 
magnitude of CSF cystatin C reductions in ALS patients compared to relevant disease control 
populations.  All studies on this topic have lacked adequate numbers of mimic disease controls, 
and most have supplemented these numbers by including patients with neurological diseases 
that are unlikely to be confused with ALS, and therefore may have confounded the results.  In 
fact, qualitative observations from my work suggest that patients with neurodegenerative 
disorders other than ALS exhibit higher CSF cystatin C levels than patients with 
neuroinflammatory disorders and other neurological conditions.  This would have reduced the 
apparent effect size, as the majority of ALS mimic diseases are classified as neurodegenerative.  
Therefore, the diagnostic utility of this protein remains ambiguous at this time.  Future studies 
including a larger number of appropriate mimic disease controls may reveal a more robust and 
consistent effect than that which was observed in my analysis.  Alternatively, clinical diagnostic 
applications may be limited to the inclusion of cystatin C in a multi-biomarker panel to improve 
the sensitivity or specificity of diagnostic performance.  
 Finally, I also reported the first evaluation of plasma cystatin C for diagnostic utility in 
ALS.  Plasma cystatin C levels in both ALS patients and neurological disease controls were 
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found to be equivalently elevated relative to healthy controls.  This indicates that systemic 
elevations in cystatin C are nonspecific markers of some neurological disease states, and do 
not carry diagnostic specificity for ALS.  Accordingly, these elevations are unlikely to result from 
ALS-specific pathology.  Instead, they may arise from more general effects of neurological 
illness on overall systemic health.  
5.1.1.2 Surrogate Utility 
CSF cystatin C has not been previously assessed for surrogate biomarker utility in ALS.  In this 
study, I conducted an evaluation of the change in CSF cystatin C levels over time, and its 
correlations with disease progression.  The longitudinally collected samples that enabled this 
analysis were a rare and valuable resource, but were not numerous enough to permit a 
comprehensive evaluation of the surrogate utility of cystatin C.  Therefore, the findings only 
provide a preliminary view of the longitudinal behavior of cystatin C and its potential for 
surrogate biomarker applications.   
 In all ALS patients combined, CSF cystatin C levels did not appear to change 
significantly over time.  However, when patients were separated into two groups according to 
clinical progression speed (fast vs. slow progressors), the groups showed opposing trends in 
longitudinal cystatin C levels, which may have been eliminated by summation in the combined 
group analysis.  Correlation analyses comparing longitudinal cystatin C changes with paired 
clinical changes in all patients may have failed to reveal significant relationships for the same 
reason.  Overall, these findings indicate that CSF cystatin C is unlikely to be useful as a 
universal surrogate marker of disease progression in ALS.  It remains possible that longitudinal 
changes in CSF cystatin C may correlate with disease pathology and functional losses in 
patients with more rapidly progressive phenotypes.  However, there were inadequate numbers 
of patients in this study to statistically assess these correlations for patient subgroups. 
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 Perhaps a more intriguing possibility for the application of these results is the use of 
cystatin C change as a marker of progression phenotype.  The data suggest that the direction of 
longitudinal cystatin C change may be an indicator of disease progression speed in individual 
patients.  If this factor is found to change proportionally with changes in progression speed in 
individual patients, it could potentially be used as a marker of alterations in disease course (with 
possible corresponding changes in pathophysiological characteristics).  In this case, the 
reversal of a downward trend or the initiation of a rapid increase in longitudinal CSF cystatin C 
levels could potentially serve as a therapeutic endpoint, which would signify the successful 
slowing of disease progression and underlying pathogenic processes.  This could potentially 
increase the efficiency of clinical trials in evaluating the efficacy of prospective treatments.  
However, extensive additional characterization would be required to confirm the utility of CSF 
cystatin C for this application. 
5.1.1.3 Prognostic Utility 
CSF cystatin C has not been previously assessed for prognostic utility in ALS.  In this study, I 
identified a significant, direct relationship between CSF cystatin C concentration and the 
duration of patient survival.  This indicates that CSF cystatin C levels evaluated during the 
symptomatic phase of the disease show strong potential for clinical use as prognostic 
biomarkers of expected survival.  With further characterization to document its predictive 
capacity in various patient subgroups, this protein could be utilized as a prognostic biomarker to 
assist in clinical decision making and to aid in clinical trial design and efficiency.      
5.1.2 Functional implications of Cystatin C Differences 
My assessment of cystatin C activity in the CSF of ALS patients, healthy controls, and 
neurological disease controls revealed that the kinetics of its activity against cathepsins and 
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calpains does not differ between these groups.  Therefore, variations in CSF cystatin C 
concentration relative to normal controls can be inferred to produce proportional variations in 
cystatin C activity.  This conclusion allows further interpretation of the results of my biomarker 
evaluation and other published reports of CSF cystatin C abundance in ALS. 
 The identified reduction in CSF cystatin C concentration in ALS patients relative to 
healthy individuals would be accompanied by proportionally diminished total cystatin C activity.  
Additionally, because cystatin C is the predominant CPI in the CSF, this change is likely to have 
a large impact on the total CPI activity within the CSF.  A significant reduction in this activity 
could potentially contribute to CNS damage by generating an imbalance between endogenous 
cysteine protease activity and protease inhibitor activity.  This situation is already thought to 
contribute to CNS damage in other neurodegenerative disorders including Alzheimer's disease 
[211] and Multiple Sclerosis [212, 213].  Emerging evidence also suggests that a similar 
imbalance may exist in ALS and contribute to motor neuron degeneration.   
 Cathepsins are papain-like cysteine proteases that function within lysosomes and 
extracellular fluid, and are inhibited by cystatin C in both locations [109, 113].  Cathepsin 
expression is increased following CNS injury [109, 214], and has been shown to exacerbate 
neuronal damage in this context [150, 215].  In ALS, the expression of cathepsins D and B has 
been reported to be significantly increased in the post-mortem spinal cord of ALS patients [191].  
Additionally, cathepsin B levels are elevated in transgenic SOD1 mice prior to symptom onset, 
and the expression of cathepsins D and B both increase with disease progression in these 
animals [191].  These findings suggest a state of increased cathepsin production in ALS.  
Cathepsins can then be released into the extracellular fluid and CSF by exocytosis [109].  
Activated microglia in particular, which are present during ALS progression, are known to 
secrete several cysteine proteases including cathepsin B [200].  Damaged and dying cells can 
also release multiple cathepsins into the extracellular fluid.  The intersection of these processes 
in ALS could lead to an excess of cysteine protease activity in the extracellular fluid and CSF.  
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This, in conjunction with the reduced overall CPI activity, could result in proteolytic tissue 
damage, including extracellular matrix destruction and the induction of both inflammation and 
neuronal apoptosis [109].  Interestingly, this process could also damage vascular elements and 
lead to blood-CNS barrier compromise in ALS.   
 Increased intracellular cathepsin levels may also contribute to neuronal degeneration.  In 
addition to the previously mentioned increases in cathepsin expression in ALS, increased 
cathepsin B protein levels have also been observed in degenerating LMNs and surrounding 
astrocytes in SALS [216].  Both this particular cathepsin and cathepsin D have been suggested 
to play pro-apoptotic roles in some models of apoptosis [149, 216-219].  Cystatin C has been 
shown to inhibit intracellular cathepsins, but it is not known whether the specific proteins that 
participate in this interaction are all generated within the cell, or if uptake of extracellular cystatin 
c contributes to this process.  If uptake does occur, as it does in non-neuronal cell lines [205], 
then reduced uptake due to lower extracellular cystatin c concentration could potentially 
contribute to the development of excess intracellular cathepsin activity, and subsequent 
neuronal damage. 
  Cystatin C may also interact with calpains in both extracellular and intracellular 
locations.  Calpains are calcium-dependent papain-like cysteine proteases that are activated 
under conditions of elevated intracellular calcium, including apoptosis, necrosis, and 
excitotoxicity [192, 220].  They are upregulated following CNS trauma and have been shown to 
contribute to neurodegeneration [190] in vivo, and excitotoxicity-mediated cell death in motor 
neuron-like cell cultures [221].  These findings suggest that Calpains may become activated in 
motor neurons in ALS due to excess glutamatergic neurotransmission, and may subsequently 
contribute to motor neuron damage and death.  This hypothesis is supported by the observation 
of calpain activity in both the spinal cord and cortex of transgenic SOD1 mice [222, 223], as well 
as the finding that a specific calpain inhibitor prolongs viability and reduces the development of 
pathological SOD1 inclusions in primary motor neuron cultures isolated from these transgenic 
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mice [192].  However, calpain expression and activity have not been directly evaluated in 
human disease.  Nevertheless, as in the case with cathepsins, reduced cystatin C activity in 
ALS could potentially result in excess neurotoxic calpain signaling.   
 Reduced CSF cystatin C levels may also affect neuronal survival by mechanisms 
independent of its activity as a CPI.  It is proposed to exert neuroprotective effects through the 
regulation of cellular proliferation [194, 195], inhibition of amyloid-beta oligomerization [109, 
196-198], and the induction of macroautophagy [193].  Of these actions, the induction of 
macroautophagy is the activity most likely to relate to ALS pathogenesis.  Macroautophagy is a 
lysosome-dependent degradation pathway that results in both the clearance of damaged 
organelles, toxic proteins, and pathogenic protein aggregates, as well as the regeneration of 
cellular components [109, 182, 224].  It is thought to be neuroprotective in neurodegenerative 
disorders featuring protein aggregation, such as Alzheimer's disease, Huntington's disease, 
Parkinson's disease, and ALS [199, 224].  Extracelluar cystatin C has demonstrated a dose-
dependent protective effect on cultured neurons, which was mediated by the induction of 
autophagy [193].  This suggests that reductions in extracellular and CSF cystatin C in ALS may 
also result in the loss of a CPI activity-independent neuroprotective function in ALS.  However, 
pharmacologic enhancement of autophagy in a transgenic rodent model of ALS was recently 
reported to accelerate motor neuron degeneration and shorten life span [224].  Thus, the role of 
autophagy in ALS remains unclear, and there is inadequate evidence to make conclusions 
regarding any neurotoxic or neuroprotective effects of altered cystatin C concentration relating 
to the possible induction of autophagy in ALS. 
 Overall, the preponderance of evidence points to a neuroprotective role of cystatin C in 
ALS.  This is in agreement with my findings regarding the longitudinal characteristics of cystatin 
C abundance and the prognostic properties of cystatin C.  Increasing CSF cystatin C levels 
were associated with slower disease progression and higher baseline cystatin C levels were 
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associated with longer patient survival.  Both of these relationships indicate a protective role of 
cystatin C in slowing disease progression. 
 The apparent protective role of cystatin C in ALS pathogenesis, in addition to the 
documented reductions in its CSF abundance, suggest that the upregulation of cystatin C may 
be of therapeutic value in treating ALS.  Furthermore, other pharmacologic manipulations which 
reduce cysteine protease activity or promote CPI activity within the CNS may also produce 
neuroprotective effects. 
5.2 CSF FREE HEMOGLOBIN AND ALS 
5.2.1 A Biomarker of BCNSB Damage? 
In this work, elevations in CSF free hemoglobin were identified to occur more frequently in ALS 
patients than in healthy controls and neurological disease controls.  This finding contributes to 
the growing body of evidence suggesting that BCNSB damage occurs in ALS.  This evidence 
includes the elevation of the CSF albumin/serum albumin ratio in many ALS patients [161-163], 
post-mortem observations of endothelial cell activation in the ALS spinal cord [164, 165], and 
well-characterized BBB and BSCB pathology in animal models of FALS [153, 167-169].  
However, one recent study evaluated ALS patients by MRI and failed to find evidence of active 
cerebral microbleeds or resulting hemosiderin deposits [225].  Given this finding, and the limited 
post-mortem evidence of BBB/BSCB damage in ALS patients, it remains difficult to conclude 
whether BCNSB disruption actually occurs during human disease.   
 A potential alternative explanation for the observed presence of CSF hemoglobin is that 
it is locally produced within the CNS.  Several human neuronal types have been shown to 
produce hemoglobin proteins [226, 227], and expression appears to be increased by responses 
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to hypoxia.  At this time, there is no evidence that these proteins are secreted, but they could 
potentially be released into the extracellular fluid by damaged or dying neurons.  However, it 
seems unlikely that the relatively high CSF hemoglobin levels observed in some ALS patients 
could be produced by passive release from a limited number of dying motor neurons. 
5.2.2 Implications for Disease Pathogenesis 
If BCNSB damage in ALS does occur, it likely follows a sporadic, transient course, as the 
majority of patients examined at any given time do not exhibit evidence of acute BCNSB 
breakdown.  BBB and BSCB damage has been proposed to result from a primary disorder of 
CNS hemodynamics, and to be the initiating factor in ALS pathogenesis [166].  A second, more 
likely hypothesis is that respiratory insufficiency in ALS results in hypercapnia, which results in 
altered CSF flow and BCSFB insufficiency [228].  BBB and BSCB damage could also result 
from a dysregulation of cysteine protease activity, as noted above.  Regardless of its causes, 
BCNSB damage would result in further CNS damage due to edema, inflammation, and the entry 
of neurotoxic plasma-derived proteins, such as hemoglobin [154].  Hemoglobin also has a 
mechanistic connection to ALS, as it induces dose-dependent neurotoxic effects through an 
oxidative mechanism [170], and oxidative damage is a known component of ALS 
pathophysiology.  
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6.0  FUTURE DIRECTIONS 
6.1 CYSTATIN C AS AN ALS BIOMARKER 
6.1.1 Diagnostic Utility 
To more fully evaluate CSF cystatin C for diagnostic biomarker utility, its levels during the time 
of diagnostic uncertainty need to be compared to those of patients with neurological disorders 
that mimic ALS.  Additionally, a much larger number of patients and controls should be 
evaluated.  To accomplish this goal, multiple institutions that receive referrals for the evaluation 
of suspected ALS should be recruited for study participation.  All new patients with the 
possibility of an ALS diagnosis should be offered the opportunity to participate in the study, and 
CSF should be collected at the initial visit and as many subsequent visits as possible.  All 
participating patients should be followed throughout the course of disease, and their ultimate 
diagnoses should be recorded.  CSF cystatin C levels should then be compared retrospectively 
between patients who are confirmed to have ALS and patients who are determined to have 
alternate diagnoses.  For this comparison, patients from each group should be matched 
according to the time from symptom onset and degree of disease progression.  Additionally, the 
diagnostic parameters of CSF cystatin C concentration should be separately evaluated for 
patients with various presenting phenotypes (i.e. limb vs. bulbar onset, or UMN symptom 
predominance vs. LMN symptom predominance) to determine if cystatin C evaluation is more 
diagnostically useful in specific patient subpopulations.  The findings of this study would clarify 
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and quantify the individual utility of CSF cystatin C as a diagnostic biomarker for specific ALS 
subpopulations, and also reveal its potential for contributing to a diagnostic biomarker panel.   
6.1.2 Surrogate Utility 
CSF cystatin C levels have not demonstrated any correlation with clinical measures of disease 
progression, and therefore further investigation of these measurements for direct surrogate 
utility in ALS is probably not warranted.  However, there is a possibility that the direction of 
longitudinal change in cystatin C is indicative of progression speed, and that alterations in the 
direction of change could be closely associated with alterations in the rate of disease 
progression.  If this is the case, large increases in longitudinal cystatin C levels could potentially 
be used as an endpoint in clinical trials, to signify efficacy of the examined treatment in slowing 
disease progression.  To test this hypothesis, it would be necessary to collect multiple 
longitudinal CSF samples from ALS patients, and also gather functional and radiographic 
progression data at each collection time point.  The data could then be analyzed to determine if 
longitudinal cystatin C reliably increases prior to, or simultaneously with, reductions in 
progression speed.  The efficiency of this study could be increased by selecting patients who 
exhibit variable, rather than steady, disease progression, and patients who are beginning 
therapeutic protocols or trials.  Such patients would be more likely to exhibit changes in disease 
progression for subsequent analysis. 
6.1.3 Prognostic Utility 
Of all its potential biomarker applications, CSF cystatin C concentration shows the highest 
potential for clinical utility as a prognostic biomarker.  However, additional validation is required 
before this measurement can be utilized in clinical applications.  To accomplish this, CSF 
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cystatin C levels should be measured in a large set of patients at multiple clinical sites.  
Demographic information, clinical disease phenotype and progression information, and 
treatment information should be collected for each patient, and survival should be tracked.  After 
adequate time has elapsed to enable the statistical assessment of survival for the majority of the 
enrolled patients, the prognostic utility of cystatin C should be evaluated in multiple patient 
subgroups.  This will allow the prognostic capacity of cystatin C to be thoroughly characterized 
for patients with varying demographics, phenotypes, and degrees of disease progression.  Once 
this information is known, CSF cystatin C measurements can be reliably interpreted for 
prognostic significance in both clinical and research settings.   
6.2 THE ROLE OF CYSTATIN C IN ALS PATHOGENESIS 
6.2.1 Further Characterization of Changes in ALS Patients 
Reductions in CSF cystatin C concentration in ALS have been documented, but changes within 
the neuropil have not been directly examined.  Post-mortem tissue would need to be used for 
this analysis, as CNS tissue cannot be safely sampled by biopsy.  First, cystatin C expression in 
the motor cortex, spinal cord, and choroid plexus of ALS patients and healthy controls should be 
examined by RT-PCR.  This experiment will determine if cystatin C is differentially regulated in 
regions of motor neuron degeneration, and  if its expression is downregulated in the choroid 
plexus.  Secondly, the concentration of cystatin C within motor cortex and spinal cord tissue 
lysates should be quantified to determine if observed changes in expression are mirrored by 
proportional changes in total protein levels.  If possible, the activity of cystatin C within tissue 
lysates should also be assessed to determine if cystatin C demonstrates equivalent activity 
kinetics in ALS patients and controls.  It is likely that cystatin C activity in ALS patients will be 
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less than the amount predicted by its concentration due to the aggregation of this protein in 
Bunina bodies.  These experiments would clarify the functional impact of cystatin C alterations 
in ALS.   
 Similar experiments should be conducted to evaluate the expression and total protein 
levels of specific cystatin C target proteases that may be involved in neural damage, such as 
cathepsins B and D.  The results of this experiment would determine whether an imbalance 
exists between cysteine protease levels and CPI activity in the brain and spinal cord of ALS 
patients. 
 Finally, double-immunoflorescence experiments should be completed to determine 
which apoptosis-related cathepsins and calpains co-localize with cystatin C in neurons and glia, 
and in which cellular compartments these interactions occur.  These findings will assist in the 
interpretation of expression and activity data. 
6.2.2 Effect on motor neurons in vitro  
A first step in deciphering the ways that extracellular cystatin C may affect motor neurons is to 
determine whether this protein is internalized by these cells.  This can be accomplished by 
uptake experiments using flow cytometry and confocal microscopy to determine if externally 
applied cystatin C is internalized by primary motor neurons. 
 Next, the direct effects of cystatin C on motor neuron survival and morphology could be 
examined using primary motor neuron cultures.  Previous reports have suggested that Cystatin 
C modulates neuronal apoptosis following exposure to oxidative stress, and possibly also 
excitotoxicity.  Both exogenous and endogenous alterations in Cystatin C expression could be 
tested by manipulating the culture media and employing gene delivery and RNAi techniques, 
respectively.  Survival, morphologic indicators of neuronal health, and markers of apoptosis 
could then be quantified at baseline and under conditions of oxidative and/or glutamatergic 
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stress. These data could then be interpreted within the context of Cystatin C concentration and 
activity levels (determined in the previous experiments) in order to decipher the potential roles 
that Cystatin C could play in the pathogenesis of ALS. 
6.2.3 Effect on motor neurons in vivo 
Conclusions from the pathological examinations of human tissue and studies of cultured cells 
should be confirmed in vivo using animal models. 
 A down-regulation of CSF cystatin C could be induced via RNAi injection into the choroid 
plexus.  This would allow the evaluation of any overt phenotype and/or neuropathology that 
results from the isolated reduction of CSF cystatin C.  This experiment could also be performed 
in a rodent model of ALS to determine if reduced CSF cystatin C exacerbates the disease 
phenotype.  Similarly, reductions in intraneuronal cystatin C expression could be modeled by 
crossing cystatin C conditional knockout mice with transgenic mice modeling FALS. 
 Furthermore, the protective properties and therapeutic value of cystatin C could also be 
examined by the up-regulation of this protein in animal models.  Cystatin C levels within the 
CSF could be augmented by direct infusion into the lateral ventricles of ALS mice.  Alternatively, 
increased cellular expression of cystatin C could be accomplished by creating transgenic mice 
that overexpress this protein, and then crossing them with ALS mice.  These experiments would 
provide an initial assessment of the therapeutic potential of cystatin C upregulation for the 
treatment of ALS. 
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6.3 BLOOD-CNS BARRIER AND ALS BIOMARKERS 
Continuing work should seek to confirm that elevated CSF free hemoglobin is a specific marker 
of BCNSB compromise, and to further characterize the occurrence of this damage in ALS 
patients.  Plasma should be collected concomitantly with CSF in all ongoing work, in order to 
determine if elevations in CSF free hemoglobin correlate with elevated CSF albumin/serum 
albumin ratios.  A positive correlation would  strengthen the hypothesis that free hemoglobin 
elevations are the result of BCNSB damage. 
Additionally, a set of patients exhibiting elevated CSF free hemoglobin should be 
evaluated by MRI as quickly as possible following the collection of a positive CSF sample.  This 
technology can be used to identify both active microbleeds and hemosiderin deposits resulting 
from previous microbleeds.  This procedure could potentially provide structural evidence of 
BCNSB damage in patients with elevated CSF free hemoglobin. 
 Finally, longitudinal samples should be assessed to determine if elevations in CSF 
hemoglobin are continuous or transient throughout the course of disease, and if ALS patients 
with low initial CSF hemoglobin levels ever exhibit evidence of BCNSB breakdown during 
disease progression.  Clinical data should also be collected and assessed to determine if CSF 
hemoglobin levels correlate with the rate of ALS disease progression.  These assessments 
would determine the frequency and duration of BCNSB breakdown events in ALS patients, and 
would help to clarify the potential role of this phenomenon in ALS pathogenesis.   
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